症例から学ぶ婦人科腫瘍学入門

出版社： 永井書店
著者：
発行日： 2006-07-20
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 4815917582
電子書籍版： 2006-07-20 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

15,400 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

本書は、婦人科腫瘍について病理形態学を中心にした病態と最新の細胞分子生物学に基づいた疾病概念の理解を深め、臨床的ＥＢＭの理解とその限界を学ぶことを目的としている。とくに金沢大学産婦人科において診療した300点を超える症例をカラー写真で呈示、また教室での日常の診療や臨床論文抄読会・臨床カンファレンスでの討論を通じて構築された基本的理念と具体的治療計画を記載し、日常診療の現場で最良の治療を実践するために大いに役立つ指針書となっている。

目次

  • 症例から学ぶ婦人科腫瘍学入門

    ―目次―

    第1章　臨床と病理―そのコミュニケーション―
    第2章　外陰・膣の疾患
    第3章　子宮頸部の疾患
    第4章　子宮体部の疾患
    第5章　卵巣の疾患
    第6章　卵管・子宮広間膜・腹膜の腫瘍―卵管癌―
    第7章　子宮内膜症
    第8章　妊娠性絨毛性疾患
    第9章　性器感染症とその関連病変
    第10章　遺伝性（家族性）癌症候群

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第2章 外陰・腟の疾患

P.3 掲載の参考文献
1. 井上正樹 : 外陰癌根治手術. 手術のポイント特別号, 産婦実際, 46 : 1659-1663, 1997.
 
2. 山田衛ほか : 原発性膣癌の臨床的観察. 産婦実際 15 : 650-654, 1966.
 
3. Antman KH : Adjuvant therapy of sarcoma of soft tissue. Seminor Oncol 24 : 556-560, 1997,
 
4. Berek JS, et al : Concurrent cisplatin and 5-fluorouracilo chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 42 : 197-201, 1991.
PubMed
5. Brinton LA, et al : Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol 38 : 49 50, 1990.
 
6. Brisigotti M, et al : Verrucous carcinoma of the vulva : a clinicopathological and immnunohistochemical study of five cases. Int J Gynecol Pathol 8 : 1-7, 1989.
 
7. Caterson RRJ , et al : Carcinoma of the vulva in two young renal allograft receipients. Transplant Proced 16 : 559, 1984.
 
8. Chyle V, et al : Definitive radiation therapy for carcinoma of the vagina. Int J Radiat Oncol Biol Phys 35 : 891-905, 1996.
PubMed
9. Curry SL, et al : Positive lymph nodes in vulvar squamous carcinoma. Gynecol Oncol 9 : 63-67, 1980.
PubMed
10. Daling JR, et al : Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 135 : 180-189, 1992.
PubMed
11. Downey GO, et al : Condylomatous carcinoma of the vulva with special reference to human papillomavirus DNA. Obstet Gynecol 72 : 68-72, 1988.
PubMed
12. FIGO : Modification in the staging for stage I vulvar and stage I cervical cancer. Int J Gynaecol Obstet 50 : 215-216, 1995.
 
13. Fanning J, et al : Paget's disease of the vulva : prevalence of associated vulvar adenocarcinoma, invasive Paget's disease and recurrence after surgical excision. Am J Obstet Gynecol 180 : 24-27, 1999.
PubMed
14. Gissmann L, et al : Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 80 : 560-563, 1983.
PubMed
15. Goldblum JR, et al : Vulvar Paget's disease : A clinicopathologic and immunohistochemical study of 19 cases. Am J Surg Pathol 21 : 1178-1187, 1997.
 
16. Gray L, et al : In situ and early invasive carcinoma of the vagina. Obstet Gynecol 34 : 226-230, 1969.
PubMed
17. Greelhoed GW, et al : Carcinoma in situ of the vagina following treatment for carcinoma of the cervix. A distinctive clinical entity. Am J Obstet Gynecol 124 : 510-1511, 1976.
 
18. Hacker NF : Vulvar Cancer. In : Bereck JS&Hacker NF ; Practical Gynecologic Oncology, 3rded, Lippincott, Williams&Wilkins, New York, 2000.
 
19. Herbst AL, et al : Adenocarcinoma of the vagina. N Engl J Med 284 : 878-881, 1971.
 
20. Herbst AL, et al : An analysis of 346 cases of clcar cell adenocarcinoma of the vagina and cervix with emphasison recurrence and survival. Gynccol Oncol 7 : 111-122, 1979.
 
21. Hilger R, et al : Embryonal rhabdomyosarcoma of the vagina : A clinicopathologic review. Am J Obstet Gynecol 107 : 484-498, 1970.
 
22. Iversen T, et al : Individualized treatment of stage I carcinoma of the vulva. Obstet Gyllecol 57 : 85-88, 1981.
 
23. Jones RW, et al : Vulvar intraepithelial neoplasia. III : A clillical study of the outcome in 113 cases with relation to the later developmcnt or invasi vulvar carcinoma. Obstet Gynecol 84 : 741-745, 1994.
 
24. Jones RW, et al : Vulvar intraepithelial neoplasia. Obstet Gynecol 106 : 1319- 1326, 2005.
 
25. Kuppers V, ct al : Risk factors for recurrem VIN : role of multifocality and grade of disease. J Reprod Mcd 42 : 140-144, 1997.
 
26. Kurman RJ, et al : Basaloid and warty carcinoma of the vulva. Distinctive types of squalllous cell callcilloma frequently associated with human papillomavirus. Am J Surg Pathol 17 : 133-145, 1992.
 
27. Leibowitch M, ct al : The epithelial changc associated with squamou : cell carcinoma of the vulva : a review of the clinical histoligical and viral findings in 78 women. Br J Obstet Gynecol 97 : 1135-1139, 1990.
 
28. Lnehan PM, et al : Vaginal intraepithelial neoplasia : Biologic aspects and managemenL Obstet Gynecol 68 : 333-337, 1986.
 
29. Mazur MT, et al : Metastases to the female genital tract. Analysis of 325 cases. Cancer 53 : 1978-1984, 1984.
 
30. Parkcr RT, et al : Operative management of early invasive epidermoid carcinoma of the vulva. Am J Obstct Gynecol 123 : 349-351, 1975.
 
31. Peters WA, et al : Primary sarcoma of the adult vagina : a clinicopathotologic study. Obstet Gynecol 65 : 699-704, 1985.
 
32. Petru E, et al : Primary malignant mclanoma of the vagina. Longterm remission following radiation thcrapy. Gynecol Oncol 70 : 23-26, 1998.
 
33. Podratz KC, et al : Carcinoma of the vulva : analysis of treatment failure. Am J Obstet Gynecol 143 : 340-345, 1982.
PubMed
34. Qualman S, et al : Intergroup rhabdolnyosarcoma study : update for pathologists. Pediatr Dcv Pathol 1 : 550-561, 1998.
 
35. Rettenmaier MA : Vulvar intraepithelial ncoplasia III : Occult cancer and the impact of margin status on recurrence. Obstet Gynecol 93 : 633-634, 1999.
PubMed
36. Russel AH, et al : Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrentsquamoug. cell carcinoma of the vulva. Gynecol Oncol 47 : 14-20, 1992.
 
37. Sarcoma Meta-analysis Collaboration : Adjuvant cheInotherapy for localized soft-tissue sarcolna of adult. Lancet 350 : 1647-1654, 1997.
PubMed
38. Tazvassoli FA, et al : Smooth muscle tumors of the vagina. Obstet Gynecol 53 . 689-693, 1979.
 
39. Thomas G, et al : Concurrent radiation and chemothcrapy in vulvar carclnoma. Gynecol Oncol 34 : 263-267, 1989.
 
40. Whalton JT, et al : Microinvasive carcinoma of the vulva. Am J Obstet Gynecol 118 : 159-165, 1974.
 
41. Wheelock JB et al : Primary carcinoma of the Bartholin gland. A report of ten cases. Obstct Gynecol 63 : 820-824, 1984.
PubMed
42. Zaino RJ, et al : Discases of the vagina. In : Kurman RJ (ed), Blaustein's Pathology of the Female Genital Tract. 5th ed Springer, New York, 2001.
 

第3章 子宮頸部の疾患

P.23 掲載の参考文献
1. 久道茂ほか : がん検診の有効性評価に関する研究. 日本公衆衛生協会, 1998.
 
2. 斎藤俊章ほか : 子宮頸部癌の広がり診断はどこまで可能か-surgical staging-. 産婦 58 : 1499-1505, 1991.
 
3. 婦人科腫瘍委員会報告 : 日産婦誌 54 : 697-792, 2002.
 
4. 婦人科腫瘍委員会報告 : 日産婦誌 57 : 990-1046, 2005.
 
5. 万代昌紀ほか : 子宮頸癌の初期病変について. 産婦治療 77 : 394-397, 1998.
Medical*Online
6. Abeler V, et al : Alveolar soft-part sarcorna in the uterine cervix. Arch Pathol Lab Med 113 : 1179-1183, 1989.
 
7. Abell MR : Sarcoma and carcinosarcomas of the uterine cervix. Cancer 31 : 1176-1192, 1973.
PubMed
8. An HJ, et al : Correlation of cervical carcinoma and precanccrous lesions with human papillomavirus genotypes with the HPV DNA chip microarray method. Cancer 97 : 1672-1680, 2003.
PubMed
9. An HJ, et al : Prevalencc of human papillomavirus DNA in various histological subtype of cervical adenocarcinoma : a popularion-based study. Mod Pathol 18 : 528-534, 2005.
PubMed
10. Azodi M, et al : Adenocarcinoma in situ of the cervix. Management and outcome. Gynecol Oncol 73 : 348-353, 1999.
PubMed
11. Baalbergen A, et al : Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 92 : 262-267, 2004.
PubMed
12. Benedetti-Panici P, et al : Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cancer. J Clin Oncol 20 : 179-188, 2001.
 
13. Berek JS, et al : adenocarcinoma of the uterine cervix : histological variablc : associated with lymph node metastases and survival. Obstet Gynecol 65 : 46 52, 1985.
 
14. Borysicwicz LK, et al : A recombinant vaccine virus encoding huniaii papillomavirus type 16 and 18 E6 and E7 protein as immunotherapy for cervical cancer. Lancet 347 : 1523-1527, 1996.
 
15. Bosch FX, et al : International biological study on cervical cancer study group ; a prevalaence of human papillonlavirus in cervical cancer : world wide perspectivc. J Natl Cancer Inst 87 : 796-802, 1995.
 
16. Bosch FX, et al : The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 : 244-265, 2002.
PubMed
17. Brand E, et al : Rhabdomyosarcoma ofthe uterine cervix. Sarcoma botryoides. Cancer 60 : 1552-1560, 1987.
 
18. Brock KE, et al : Smoking and infectious agents and risk of in situ cervical canccr in Sidney, Autralia. Cancer Res 49 : 4925-4928, 1989.
 
19. Brown JV, et al : Ovarian metastases are rare in srage I adcnocarcinoma of the cervix. Obstct Gynecol 76 : 623-628, 1990.
 
20. Brown LJ, et al : Cervical glandular atypia. Associated with squamous intraepithelial neoplasia : a premalignant lesion. J Clin Pathol 39 : 22-28, 1986.
PubMed
21. Burghart E, et al : Results of surgical treatment of 1028 ccrvical cancers studied with volumetry. Cancer 70 : 648-655, 1992,
 
22. Byrne MA, et al : The common occurrence of human papillomavirus neoplasia in women infected by HIV. AIDS 3 : 379-382, 1989.
PubMed
23. Chang HC, et al : Neoadjuvant chemotherapy with cisplatin, vincristine and bleomycin and radical hysterectomy in early-stage bulky cervical carcinoma. Cancer Chemother Pharmacol 30 : 281-285, 1992.
 
24. Christensen ND, et al : Immunization with virus-like particles induces long-term protection of rabbit aginst challenge with cotton rabitt papillomavirus. J Virol 70 : 960-965, 1996.
 
25. Cox JT, ct a1 : Human papillomavirus tcsting by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undctermined significancc. Am J Obstet Gynecol 172 : 946-954, 1995.
 
26. Creasman WT, et al : Carcinoma of the cervix associated with pregnancy. Obstet Gynecol 36 : 495-501, 1970.
PubMed
27. Curtin JP, et al : Paclitaxel : an active agent in nonsquamous carcinomas of the uterine cervix. J Clin Oncol 19 : 1275-1278, 2001.
 
28. Cuzick J, et al : Management of women who testpositive for high-risk typcs of human papillomavirus. the HART study Lancct 362 : 1871-1876, 2003.
 
29. Dimopoulos MA, et al : Combination of ifosfamide, paclitaxel and cisplatin for the treatment of metastasis and recurrent carcinoma of the uterine cervix. Gynecol Oncol 85 : 476-482, 2002.
PubMed
30. Durst M, et al : A papillomavirus DNA from a cervical carcinoma and its plevalence in cervical biopsysample from different geographic regions. Proc Natl Acad Sci USA 80 : 3812-3815, 1983.
 
31. Dyson N, et al : The human papillomavirus-16E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 : 934-937, 1989.
 
32. Eifel PJ, et al : Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59 : 38-44, 1995.
PubMed
33. Enomoto T, et al : Clonl analysis of high grade squamous intraepithelial lesions of the uterine cervix. Int J Cancer 73 : 339-344, 1997.
PubMed
34. Eustace D, et al : Interleukin-6 functions as a autocrine growth factorin cervical carcinomas in vitro. Gynecol Oncol 50 : 15-19, 1993.
 
35. Farely JH, et al : Adenosquamous histology predicts a poor outcome for patients with advanced-stage but no early stage cervical carcinoma. Cancer 97 : 2196-2202, 2003.
 
36. Ferris DG & Litaker MS : Colposcopy quality control by remote review of digitized cologoscopic images. Am J Obstet Gynecol 191 : 1934-1941, 2004
PubMed
37. Friedman M, et al : Modern treatment of vaginal embryonal rhabdomyosarcoma. Obstet Gynecol Surv 41 : 614-618, 1986.
PubMed
38. Fujita M, et al : Alterations of p53 gene in human primary cervical careinoma with and without human papillomavirus infection. Cancer Res 52 : 5323-5328, 1992.
 
39. Girardi F, et al : Cold-knife conization versus loop excision : histologic and clinical results of a randomized trial. Gynecol Oncol 55 : 368-370, 1994.
 
40. Golbang P, et al : Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell tumor. Gynecol Oncol 67 : 102-106, 1997.
PubMed
41. Gordon AN, et al : Sarcoma botryoides of the cervix : excision followed by adjuvant chemotherapy for preservation of reproductive function. Gynecol Oncel 36 : 119-124, 1990.
 
42. Govens, A, et al : Is radical trachelectomy a safe alternative to radical hysterectomy for patients with satge 1A-B carcinoma of the cervix? Cancer 86 : 2273-2279, 1999.
 
43. Grigsby PW, et al : A denocarcinoma of the uterine cervix : lack of evidence for a poor prognosis. Radiother Oncol 12 : 289-293, 1988.
 
44. Harro CD, et al : Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L 1 virus-like partile vaccine. J Natl Cancer Inst 93 : 284-292, 2001.
 
45. Hemminki K, et al : High prevalence of humanpapilloma transcript in all grades of cervical intraepithelial glandular neoplasia. Cancer patients. Epidemiol 11 : 347-349, 2000.
 
46. Higgins GD, et al : High prevalence of humanpapilloma transcript in all grades of cervical intraepithelial glandular neoplasia. Cancer 70 : 136-146, 1992.
 
47. Hilgarth M & Menton M : The Colposcopic screening. Eur J Obstet Gynecol Reproductive Biol 65 : 65-69, 1996.
 
48. Holowaty P, et al : Natural history of dysplasia of the uterine cervix. J Natle cancer Inst 91 : 252-258, 1999.
 
49. Iftner T & Villa LL : Human papillomavirus technologies. J Natl Cancer Inst Monogr 31 : 80-88, 2003.
PubMed
50. Inoue M, et al : A novel monoclonal antibody against squamous cell carcinoma. Jpn J Cancer Res 81 : 176-182, 1990
 
51. Inoue M, et al : Human papillomavirus type 16 in semen of partners of women with HPV infection. Lancet 399 : 1114-1115, 1992.
 
52. Inoue M, et al : Imunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 102 : 665-670, 1994.
 
53. Inoue M, et al : The evaluation of human papillomaviru, DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16 : 1-7, 2006.
 
54. Ishii K, et al : Cytologecal and cytochemical features adenoma malignum of the uterine cervix. Cancer 87 : 245-253, 1999.
PubMed
55. Jayanthi S, et al : Adenoqudmous histology predicts poor outcome in low-risk stdge Ib1 ceivical adenocarcinoma. Gynecol Oncol 91 : 558-562, 2003.
 
56. Jones NM, et al : Well ditterentiated villoglandular denocdicinoma of the uterine cervix-a clinicopdthological study ot 24 case-. Int J Gynecol Pathol 12 : 1-7, 1993.
 
57. Kaku T, et al : Early adenocarcinoma of the uterine cervix. Gynecol Oncol 65 : 281-285, 1997.
PubMed
58. Kanaya T, et al : The 5' region of the human papillomavirus type 31b upstream regulatory region acts as an enhancer which augments viral expression through the action of YY1. Virology 237 : 159-169, 1997.
 
59. Kasamatsu T, et al : Early invasive adenocarcinoma of the uterine cervix.Gynecol Oncol 85 : 327-332, 2002.
PubMed
60. Kato H, et al : Tumor antigen TA-4, in the detection of recurrence in cervical squarnous cell carcinoma. Cancer 54 : 1544-1546, 1984.
 
61. Kessler II, et al Veneral factors in human cervical cancer : evidence from marital clusters. Cancer 39 : 1912-1919, 1977.
PubMed
62. Keys HM, et al : Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky sytage IB cervical carcinoma. N Engl J Med 340 : 1154-1161, 1999.
PubMed
63. Kim JJ, et al : Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance, JAMA 287 : 2382-2390, 2002.
PubMed
64. Kiyono T, et al: Both Rb/p16 inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396 : 84-88, 1998.
PubMed
65. Kjaer SK, et al : Case-control study of risk factors for cervical neoplasia in Denmark. I : role of the male factor in women with one lifetime sexual partner. Int J Cancer 48 : 39-44, 1991.
 
66. Klaes R, et al : Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92 : 276-284, 2001.
PubMed
67. Kohlberger PD, et al : Comparative evaluation of seven cell collection devices for cervical smear. Acta Cytol 43 : 1023-1026, 1999.
PubMed
68. Koutsky LA, et al : A cohort study of the risk of cervical intraepithelial neoplasia grade 2 of 3 in to papillomavirus int\fection. N Engl J Med 327 : 1272-1278, 1992.
 
69. Koutsky LA, et al : A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 : 1645-1651, 2002.
PubMed
70. Kuragaki C, et al : Mutations in the STK 11 gene charactetize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest 83 : 35-45, 2003.
 
71. Kurian K, et al : Relation of cervical glandular intracpithekial neoplasia to microinvasive and invasive adenocarcinoma. J Clin Pathol 52 : 112- 117, 1999.
 
72. Kyo S, et al : NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. J Virol 67 : 1058-1066, 1993.
 
73. Kyo S, et al : Regualtionof eraly gene expression of human papillomaviru, type 16 by inflammatory cytokines. Virology 200 : 130-139, 1994.
 
74. Kyo S, et al : Application ot telomerase assay for the screening of cervical lesions. Cancer Res 57 : 1863-1867, 1997.
 
75. Kyo S, et al : Sp1 coopelates with c-myc toactivate transcription of human telomerase reverse transcriptase (hTERT) gene. Nucleic Acids Res 28 : 669-677, 2000.
 
76. Kyo S, et al : Expression of AP1 during cellular differentiation determines human papillomavirus E6/E6 expression in statified epithelial cells. J Gen Virol 78 : 401-411, 1997.
 
77. Lacey CJ : Genital warts in children. Papillomvirus Reviews : Current Research on Papillomaviruses. pp291-296, Leeds University Press, 1996.
 
78. Landoni F, ct al : Class II versus, Class III radical hysterectomy in stage IB-IIA cervical cancer : A Prospective randomized study. Gynecol Oncol 80 : 3-12, 2001.
 
79. Landoni F : Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 : 535-540, 1997.
PubMed
80. Lee YN, et. al : Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer. A clinical review of 954 cases. Gynecol Oncol 32. 135-142, 1989.
 
81. Lehtinen M, et al : Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia. J Clin Virol 19 : 113-122, 2000.
 
82. Liaw KL, et al : Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions J Natl Cancer Inst 91 : 954-960, 1999
PubMed
83. Lin J, et dl : Sarcoma botryoides of the cervix treated with limited surgery and chemo-therapy to reserve fertility. Gynecol Oncol 58 : 270-273, 1995.
 
84. Lorinz AT, et al : Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North America 23 : 707-730, 1996.
 
85. Manos MM, et al : Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal papanicolaou results. JAMA 281 : 1605-1610, 1999.
PubMed
86. Mant C, et al : Non-scxual transmission of cervical cancer-associated papillomviruses : Papillomvirus Report 11 : 1-5, 2000.
 
87. Matsukura T, ct al : Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancer. Virology 172 : 63-72, 1989.
 
88. Matsumine A, et al : Binding of APC to the human homolog of the Drosophilia discs large tumor suppressor protein. Science 272 : 1020-1023, 1996.
 
89. Mendenhall WM, et al : Stage IB-IIA-B caicinoma of the intact uterine cervix greater than or equal to 6cm in diameter : Is adjuvant extrafascial hysterectomy beneficial? Int J Radiat Oncol Biol Phys 21 : 899-904, 1991.
 
90. Meyel WH : Clinical characteristics and therapeutic approaches for children with soft tissue sarcomas. JCO Education book pp603-610, 2002.
 
91. Mikami Y, et al : Lobular endocervical glandular hyperplasia represents pyroric gland metaplasia? Am J Surg Pathol 24 : 323-324, 2000.
PubMed
92. Minaguchi T, et al : No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 58 : 4585-4586, 1998.
PubMed
93. Moberg PJ, et al : Adenocarcinoma ot the uterine cervix. Cancer 57 : 407-412, 1986.
 
94. Monk BJ, et al : Re-thinking the use of radiation and chemotherapy after radical hysterectomy : a clinical-pathologic analysis of a GOG, SOG, RTOG trial. Gynecol Oncol 96 : 721-728, 2005.
 
95. Montana GS, et al : Analysis of results of radiation therapy for stage II carcinoma of the cervix. Cancer 55 : 956-962, 1985.
PubMed
96. Moodley M, et al : The significance of human papillomavirus infection detected by cervical cytology among women infected with the human immunodeficiency virus. J Obstet Gynaecol 24 : 903-906, 2004.
PubMed
97. Moore DH : Chemoradiation and controversies in stage IB cervical carcinoma. Am Soc Clin Oncol Educational book 453-458, 2002.
 
98. Morris M. et al : Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer : A radiation therapy oncology group clinical trial. N Engl J Med 340 : 1137-1144, 1999.
 
99. Munger K, et al : Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20 : 7888-7898, 2001.
PubMed
100. Munger K & Howley PM : Human papillomavirus immortalization and transformation functions. Virus Res 89 : 213-228, 2002.
PubMed
101. Munoz N, et al : Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 : 518-527, 2003.
PubMed
102. Muntz HG : Adenocarcinoma in situ of the uterine cervix. Obstet Gynecol 80 : 953-939, 1992.
 
103. Murphy N, et al : p16 as a marker for cervical diagnosis. CIN and CGIN in cervical biopsies and ThinPrep(TM) smears. J Clin Pathol 56 : 56-63, 2003.
 
104. Natsume N, et al : Ovarian metastasis in stage IB and II cervical adenocarcinoma. Gynecol Oncol 74 : 255-258, 1999.
PubMed
105. Negri G, et al : P16ING4a is a useful for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunohistochemical correlation. Am J Surg Pathol 27 : 187-193, 2003.
PubMed
106. Newton R : A review of the aetiology of squamous cell carcinoma of the conjunctiva. Br J Cancer 74 : 1511-1513, 1996.
 
107. Nishikawa A, et al : p53 polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 10 : 402 407, 2000.
 
108. Nisker JA : Stage Ib cervical carcinoma and pregnancy. Report of 49 cases. Am J Obstet Gynecol 145 : 203-206, 1983.
PubMed
109. Nuovo J, et al : Treatment outcomes for squamous intraepithelial lisions. Int J Gynecol Obstet 68. 25-33, 2000.
 
110. Ostor A, et al : Microinvasive adenocarcinoma of the cervix, A ck\linicopathological study of 77 women. Obstet Gynecol 89 : 88-93, 1997.
 
111. Peters WA, et al : Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 : 1606-1613, 2000.
PubMed
112. Pirami L, et al : Analysis of HPV16, 18, 31, and 35 DNA in preinvasive and invasive lesions of the uterine cervix. J Clin Pathol 50 : 600-604, 1997
PubMed
113. Plante M, et al : Vaginal radical tracheotomy : A valuable fertility-preserving portion in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 98 : 3-10, 2005.
 
114. Quackenbush SR : Single-slide Pap smear : an acceptable alternative to the double-slide Pap smear. Diagn Cytopathol 20 : 317-320, 1999.
 
115. Reich O, et al : CINIII: long term follow-up after cold-knife conization with involved margins. Obstet Gynecol 99. 193, 2002.
 
116. Rose PG, et al : Concurrent cisplatin based radiotherapy and chemotherapy for locally-advanced cervical cancer. N Engl J Med 340 : 1144-1153, 1999.
PubMed
117. Rose PG, et al : Prolonged oral etoposide in recurrent of advanced non-squamous cell carcinoma of the cervix. J Clin Oncol 89 : 267-270, 2003.
 
118. Sablinska RE, et al : Invasive carcinoma of the cervix associated with pregnancy : correlation between patient age, advancement of cancer and gestation, and result of treatment. Gynecol Oncol 5 : 363-373, 1977.
 
119. Sardi J, et al : Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 38 : 486-493, 1990.
PubMed
120. Sagawa T, et al : Identification of antibodies against human papillomavirus type 16E6 and E7 proteins in sera of the patients with cervical neoplasias. Jpn J Cancer Res 83 : 705-713, 1992.
 
121. Sasagawa T, et al : Induction of uterine cervical neoplasias in mice by human papillomavirus type 16 E6/E7 genes. Cancer Res 52 : 4420-4426, 1992.
PubMed
122. Sasagawa T, et al : Cervical/vaginal dysplasia of transgenic mice harbouring human papillomavirus type 16E6-E7 genes. J Gen Virol 75 : 911-916, 1994.
 
123. Sasagawa T, et al : Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in Fission yeast Schzosaccharoges pombe. Virology 206 : 126-135, 1995.
PubMed
124. Sasagawa T, et al : Immunoglobulin-A and-G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intar-epithelial lesions. Int J Cancer 75 . 529-535, 1998.
 
125. Sasagawa T, et al : EBV genes expression in cervical intraepithelial neoplasia and invasive cervical cancer. A comparative study with HPV infection. Hum Pathol 31. 318-326, 2000.
PubMed
126. Sasagawa T, et al : High-risk and multiple human papillomavirus infection associated with cervical abnormalities in Japanese women. Cancer Epidemiology Biomark Prev 10 : 45-52, 2001.
 
127. Sasagawa T, et al : Mucosal immunoglobin-A and -G responses to oncogenic human papillomavirus capsids. Int J Cancer 104 : 328-335, 2003.
 
128. Sasagawa T, et al : An edible HPV vaccine using freeze-dried yeast for oral delivery of HPV-16 L 1 protein. Virus Res 110 : 81-90, 2005.
 
129. Schlecht NF, et al : Persitent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 : 3106-3114, 2001.
 
130. Schneider DL, et al : Cervicography screening for cervical cancer among 8460 women in a high-risk population. Am J Obstet Gynecol 180 : 290-298, 1999.
 
131. Segawa T, et al : The inverse relationship between FHIT abnormalities and HPV E6-E7 mRNA expression in the developument of cervical cancer. Cancer 85 : 2001-2010, 1999.
 
132. Sherman ME, et al : Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3 : dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarker Prev 12 : 1038-1044, 2003.
PubMed
133. Shumsky AG, et al : Caicmoma ot thc cetvix following conservative management of cervical intraepithelial neoplasia. Gynecol Oncol 53 : 50-54, 1994.
 
134. Smith PG, et al : Mortality of wives of men dying with cancer of the penis. Br J Cancer 41 : 422-428, 1980.
PubMed
135. Solomon D, et al : The Bethesda 2001 workshop. JAMA 287 : 2114-2119, 2002.
PubMed
136. Story A, et al : Role of a p53 polymorphism in the developument of human papillomavirus-associated cancer. Nature 393 : 229-234, 1998.
 
137. Sutton GP, et al : Phase II study ot ifosfamide and mesna in non-squamous carcinoma of the cervix. GOG study. Gynecol Oncol 49 : 48-50, 1993.
 
138. Sutton GP, et al : Ovarian metastasis in stage IB carcinoma of the cervix : a Gynecologic Oncology Group study. Am J Obstet Gynecol 166 : 50-53, 1992.
 
139. Swan DC, et al : Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 37 : 1030-1034, 1999.
PubMed
140. Szarewski A, et al : Comparison of four cytologic sampling techniques in a large family planning center. Acta Cytol 37 : 457-460, 1993.
 
141. Tase T, et al : Human papillomavirus DNA inglandular dysplasia anf microglandular hyperplasia presumed precursor of adenocarcinma of the uterin cervix. Obstet Gynecol 73 : 1005-1008, 1989.
 
142. Tenti P, et al : Analysis and clinical implication of p53 gene mutations and human papillomaviryus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. Am J Pathol 152 : 1057-1063, 1998.
PubMed
143. Tewari K, et al : Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in preganancy. Cancer 82 : 1529-1534, 1998.
 
144. Thierry F, & Yanivl : The BPV1-E2 trans-acting protein can be cither an activator or a repressor of the HPV 18 regulatory region. EMBO J 6 : 3391-3397, 1987.
PubMed
145. Thigpen JT, et al : Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix. GOG Study. Cancer Treat Rep 70 : 1097-1100, 1986.
PubMed
146. Thomas C, et al : 2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities Consensus Guideline. JAMA 287 : 2120-2129, 2002.
 
147. Ueda Y, et al : Monoclonal expression with integration of high-risk type human papillomavirus is an initial step for cervical carcinogenesis. Lab Invest 83 : 1517-1527, 2003.
 
148. Umesaki N, et al : Cervical adenocarcinoma. A novel combination chemotherapy with mitomycin C, etoposide and cisplatin for advanced or recurrent disease. Gynecol Oncol 75 : 142-144, 1999
PubMed
149. Villa LL, et al : Prophylactic quadrant HPVLIVLP in young women : a randomized double placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 : 271-278, 2005.
 
150. Vooijs PG, et al : Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 29 : 323-328, 1985.
PubMed
151. Walker AN, et al : Cervical neuroendocrine carcinoma : a cloinical and light microscopic study of 14 cases. Int J Gynecol Pathol 7 : 64-74, 1988.
 
152. Wank R : High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 325 : 723-725, 1991.
 
153. Werness BA, et al : Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 248 : 76-79, 1990.
PubMed
154. Wright TC Jr, et al : HPV-DNA testing of self-controlled vaginal samples compared cytologic screening todetect cervical cancer. JAMA 283 : 81-86, 2000.
 
155. Xu JY, et al : Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobuar endocervical glandular hyperplasia. Int J Gynecol Pathol 24 : 296-302, 2005.
PubMed
156. Yamazaki H, et al : Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer 94 : 222-227, 2001.
PubMed
157. Yoshino K, et al : FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer 85 : 6-13, 2000.
PubMed
158. Young RH, Scully RE : Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathological analysis of 13 cases. Cancer 63 : 1773-1779, 1989.
PubMed
159. Yutsudo M, et al : Functional dissociation of transforming genes of human papillomavirus type 16. Virology 166 : 594-597, 1988.
PubMed
160. Zaino RJ : Glandular lesions of the uterine cervix. Mod Pathol 13 : 261-274, 2000.
PubMed
161. Zanetta G, et al : Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocareinoma. Gynecol Oncol 64 : 431-435, 1997.
PubMed
162. Zehbe I, et al : p53 codon 72 polymorphism and various human papioolmavirus 16E6 genotypes are risk factors for cervical cancer development. Cancer Res 61 : 608-611, 2001.
 
163. Zeisler H, et al : Embryonal rhabdomyosarcoma of the uterine cervix : case report and review of the literature. Gynecol Oncol 69 : 78-83, 1998.
PubMed
164. Zemlickis, et al : Maternal and fetal outcome after invasive cervical cancer in pregnancy. J Clin Oncol 9 : 1956-1961, 1991.
PubMed
165. Zhou J, et al : Expression of vaccine recombinant HPV 16 L1 and L2 proteins in epithelial cells is sufficient for assembly of HPV virionlike particles. Virology 185 : 251-257, 1991.
PubMed
166. Zur Hauzen H : Papillomavirus and cancer : from bascic studies to clinical application. Nature Review Cancer 2 : 342-350, 2002.
 
167. Zur Hauzen H : Papillomaviruses causing cancer : evasion from hostcell control in early events in carcinogenesis. J Natl Cancer Inst 92 : 690-698, 2000.
 

第4章 子宮体部の疾患

P.89 掲載の参考文献
1. 井上正樹ほか : SERMが発生誘因となる婦人科腫瘍に関する調査小委員会報告. 日産婦誌 53 : 788-800, 2001.
 
2. 井上正樹 : 子宮体癌の分子機序. 新女性医学大系 第41巻, pp369-387, 中山書店, 東京, 2002.
 
3. 久道茂ほか : 新たながん検診手法の有効性の評価. 日本公衆衛生協会, 2001.
 
4. 蔵本博行ほか : 悪性腫瘍の予防早期発見-子宮内膜癌-. 産と婦 49 : 497-503, 2002.
 
5. 栗原操寿ほか : 子宮内膜癌に対するMPAの治療効果に関する検討. 産婦実際 34 : 517-536, 1985.
 
6. 厚生省薬務局安全課 : 乳癌, 子宮体癌における高用量酢酸メドロキシプロゲステロン投与中の血栓症の発現. 医薬品研究 23 : 664-671, 1992.
 
7. 高橋道ほか : 子宮体癌治療における傍大動脈リンパ節郭清の意義. 日本婦人科腫瘍会誌 21 : 82-86, 2003.
 
8. 田上慶子 : 若年性子宮内膜温存治療後の長期的転帰. 日産婦誌・抄録集 55: 407, 2003.
 
9. 中村俊昭ほか : 子宮体癌に対するPaclitaxel/Carboplatin併用療法の効果. 癌と化療 27 : 257-262, 2000.
Medical*Online
10. 日産婦学会子宮癌委員会 : 全国子宮体癌調査成績4報. 日産婦誌 51 : 1999.
 
11. 日産婦腫瘍委員会報告 : 日産婦誌 37 : 851-852, 1985 ; 53 : 717-735, 2001 ; 54 : 999-1053, 2002 ; 57 : 990-1046, 2005.
 
12. 宮本憲一ほか : 妊娠合併の子宮体癌の1例. 日産婦神奈川会誌 22 : 195-197, 1986.
 
13. 八杉利治 : 子宮体癌治療における傍大動脈リンパ節転移について. 日本婦人科腫瘍会誌 21 : 73-81, 2003.
 
14. 山辺徹 : 癌検診問題委員会報告・日産婦学誌 42 : 535-538, 1990.
 
15. 吉野直樹ほか : 昇圧動注化学療法が有効であった子宮内膜間質肉腫症例. 癌と化療 17 : 1773-1776, 1990.
Medical*Online
16. Abulafia O & Sherer Dm : Angiogenesis of the endometrium. Obstet Gynecol 94 : 148-153, 1999.
PubMed
17. Ambros RA, et al : Endometrial intraepithelial carcinoma : A distinctlesion specifically associated with tumors displaying serous differentiation. Human Pathol 26 : 1260-1267, 1995.
PubMed
18. Anderson WA, et al : Endometrial metaplasia associated with endometrial adenocarcinoma. Am J Obstet Gynecol 157 : 597-604, 1987.
 
19. Bell SW, et al : Problematic uterine smooth muscle neoplasia-a clinicopathologic study of 213 cases-. Am J Surg Pathol 18 : 535-558, 1994.
PubMed
20. Berchuch A, et al : Treatment of endometrial sarcoma. Gynecol Oncol 36 : 60-65, 1990.
 
21. Bigsby RM, et al : Immunohistochemical study of HER-Blg～by RM, et al : Immullol11, tochemlωl study ot HER 2/neu, epldellll. /neu, epidermal, growth factor receptor and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 79 : 9S-100, 1992.
 
22. Boronow RC, et al : Surgical staging in endometrial cancer : clinical-pathological findings of a prospective study. Obstet Gynecol 63 : 825-832, 1984.
PubMed
23. Bulun Se, et al : Regulation of aromatase expression in estrogen-responsive breast and uterine disease : from bench to treatment. Pharmacol Rev 57 : 359-383, 2005.
PubMed
24. Burke TW, et al : Prospective treatment of advanced or recurrent endometial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40 : 264-267, 1991.
 
25. Burke TW, et al : Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51 : 397-400, 1993.
 
26. Burnett AF, et al : Anastozole, an aromatase inhibitor and medroxy-progesterone acetate therapy inpremenopausal obese women with endometrial cancer. A report of two cases successfully treated without hysterectomy. Gynecol Oncol 94 : 832-834, 2004.
 
27. Caduff RF & Johston Cm : Mutation of the ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146 : 182-188. 1995
 
28. Catasus L, et al : Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial careinoma with microsatellite instability. Cancer 88 : 2290-2297, 2000.
 
29. Catasus L : Microsatellite instability in endometrial carcinomas : clinicopathologic correlation in a series of 42 cases. Human Pathol 29 : 1160-1164, 1998
 
30. Cauduff RF, et al : Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148 : 1671-1678, 1996.
 
31. Chen SS, et al : Propensity of retroperitoneal lymph node metastasis in patients with stage I sarcoma of uterus. Gynecol Oncol 32 : 215-217, 1989.
 
32. Chou CY, et al : Uterine leiomyosarcoma has degenerated cell proliferation, but not increased microvessel density compared with uterine leiomyoma. Gynecol Oncol 65 : 225-231, 1997.
 
33. Clement PB & Scully RE : Uterine tumots resembling ovarian sex-cord tumors. Am J Clin Pathol 66 : 512-525, 1976.
 
34. Clement PB, Scully RE : Mullerian adenosarcoma of the uterus. A Clinicopathological analysis of 100 cases with a review of literature. Human Pathol 21 : 363-381, 1990
PubMed
35. Creasman WT, et al : Surgical pathologic spread patterns of endometrial cancer. Cancer 60 : 2035-2041, 1987
PubMed
36. Duggan BD, et al : Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 86 : 1216-1221, 1994.
PubMed
37. Duke JM, et al : CA125 : A useful marker in endometrial careinoma. Am J Obstet Gynecol 155 1097-1102, 1986.
 
38. Dunton CJ, et al : Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. Gynecol Oncol 41 : 113-116, 1991.
PubMed
39. Eltabbakh GH & Moore AD : Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 74 : 80-85. 1999.
PubMed
40. Enomoto T, et al : K-ras activation in premalignant and malignant lesions of the human uterus. Cancer Res 51 : 5308-5314, 1991.
 
41. Enomoto T, et al : Alteration of the p53 tumor suppresor gene and its association with activation of the c-k-ras-2 protooncogene in premalignant and malignant lesions of the human endometrium. Cancer Res 53 : 1883-1888, 1993.
 
42. Enomoto T, et al : Alterations of the Rb gene and its association with ki-ras activation and p53 inactivation in endometrial adenocarcinoma. Mol Careinog 8 : 132-137, 1993.
PubMed
43. Enomoto T, et al : Alteration of the p53 tumor suppressor gene and activation of c-k-ras-2 protooncogene in endometrial adenocareinoma from Colorado. Am J Clin Pathol 103 : 224-210, 1994.
 
44. Enomoto T, et al : Analysis of clonality by amplification of short tandem repeats : Carcinomas of the female reproductive tract. Diag Mol Pathol 3 : 292-297, 1994.
 
45. Enomoto T, et al : Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 71 : 462-467, 1995.
PubMed
46. Esteller M, et al : Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Invest 76. 109-116, 1997.
PubMed
47. Esteller M, et al : hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155 : 1767-1772, 1999.
PubMed
48. FIGO : Special report on gynecologic cancer 2000. Int J Gynecol Obstet 70 : 209-304, 2000.
 
49. Feng YZ, et al : BRAF mutation in endometorial carcinoma and hyperplasia. Correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Research 11 : 6133-6138, 2005.
 
50. Fleming GF, et al : Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus Filgasrim in advanced endometrial carcinoma : a GOG study. J Clin Oncol 22 : 2159-2166, 2004.
 
51. Fleming GF, et al : Randomized trial of doxorubicin plus cisplatin versus DOX plus paclitaxel plus G-CSF in patients with advanced or recurrent endometrial carcinoma. A GOG study. Am Soc Clin Oncol (Abstract) 1498, 2000.
 
52. Fukuchi T, et al : Links beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58 : 3526-3528, 1998.
 
53. Germer O, et al : Ovarian metastasis in women with clinical stage I endometrial careinoma. Acta Obstet Gynecol Seand 83 : 208-210, 2004.
 
54. Gima T, et al : DCC gene alteration in human endometrial careinomas. Int J Canceer 57 : 480-485, 1994.
 
55. Girius NA, et al : PCR based microsatellite polymorphisms in the detection of loss of heterozygosity in fresh and archival tumor tissue. Br J Cancer 68 : 308-313, 1993.
 
56. Giuntoli Rl, et al : Retrospective review of 208 patients with leiomyosarcoma of the uterus. Prognostic indicatiors, surgical management and adujvant chemotherapy. Gynecol Oncol 89 : 460-469, 2003.
 
57. Goff BA, et al : Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38 : 46-48, 1990.
PubMed
58. Guintoli P, et al : Prognostic value of initial surgical procedure for patients with uterine sarcoma. Analysis of 123 patients. Euro J Gynec Oncol 24 : 237-240, 2003.
 
59. Gurin CC, et al : Causes and consequences of Microsatellite instability in endometrila carcinoma. Cancer Res 59 : 462-466, 1999.
 
60. Hashimoto K, et al : Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phos-phaglycerokinase gene. Gynecol Obstet Invest 40 : 204-208, 1995.
 
61. Hendrickson MR & Kempson RL : Endometrial metaplasia-proliferations frequently misdiagnosed as adenocarcinoma. Am J Surg Pathol 4 : 525-542, 1980.
PubMed
62. Honda T, et al : Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 58 : 14-19, 1994.
 
63. Hurst BS, et al : Uterine artery embolization for symptomatic uterine myomas. Fertil Steril 74 : 855-869, 2000.
PubMed
64. Ikeda T, et al : Mutational analysis of the CTNNB1 (β-catenin) gene in human endometrial cancer : frequent mutations at codon 34 that cause nuclear accumulation. Oncol Rep 7 : 323-326, 2000.
 
65. Inoue M, et al : Capacity for amine-preusor uptake and decarboxylation of argyrophil cell adenocarcinma of the endometrium. Gynecol Oncol 13 : 19-24, 1982.
 
66. Inoue M, et al : Immunohistochemical demonstration of peptide hormones in endometrial carcinomas. Cancer 54 : 2127-2131, 1984.
PubMed
67. Inoue M, et al : Immunohistochemical demonstraion of chromogranin in endometrial carcinoma with argyrophil cells. Human Pathol 17 : 841-847, 1986.
 
68. Inoue M, et al : Expression of blood grou antigens A, B, H, Lewis-a and Lewis-b in fetal, normal and malignant tissues of the uterine endometrium. Cancer 60 : 2985-2993, 1987.
 
69. Inoue M, et al : A nonsialylated high-molecular-weight glycoprotein defined by a monoclonal antibody to adenocarcinoma of the uterine endometrium. Gynecol Oncol 33 : 344-350, 1989.
 
70. Inoue M, et al : Clinicopathological characteristics of p53 overexpression in endometrial cancer. Int J Cancer 58 : 14-19, 1994.
PubMed
71. Inoue M, et al : A case-control study on risk factor for uterine endometrial cancer in Japan. Jpn J Cancer Res. 85 : 346-350, 1994.
 
72. Inoue M, Current molecular aspect of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 11 : 339-348, 2001.
PubMed
73. Ito K, et al : Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 54 : 4667-4670, 1994.
PubMed
74. Jobo T, et al Treatment for Comples atypical hyperplasia of the endometrium. Eur J Gynaec Oncol 22 : 365-368, 2001.
 
75. Jobo T, et al : Successful conservative treatment of endometrial carcinoma : report of two cases. Eur J Gynecol Oncol 21 : 119-122, 2002.
 
76. Jovanovic As, et al : Uteri of women with endometrial careinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 56 : 1917-1921, 1996.
 
77. Kanaya T, et al : Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 22 : 2352-2360. 2003.
PubMed
78. Kanaya T, et al : Association of mesmatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 124 : 89-96, 2005.
 
79. Karlsson B, et al : Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding. a Nordic multicenter study. AM J Obstet Gynecol 172 : 1488-1494, 1995.
PubMed
80. Katabuchi K, et al : Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55 : 5556-5560, 1995.
 
81. Katase K, et al : The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 82 : 1698-1703, 1998.
PubMed
82. Katz LA, et al : Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol 184. 1071-1073. 2001.
PubMed
83. Kedar RP, et al : Effect of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer preventing trial. Lancet 343 : 1318-1321, 1994.
 
84. Kelly RM & Baker WH : Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264 : 216-222, 1961.
 
85. Kendall BS, et al : Reproducibility of the diagnosis of endometrial hyperplasia, atypical yperplasia, and well-differentiated carcinoma. Am J Surg Pathol 22 : 1012-1018, 1998.
 
86. Khalifa MA, et al : Expression of EGFR, HER-2/neu, p53 and PCNA in endometrial adenocareinomas. Gynecol Oncol 53 : 84-92, 1994.
PubMed
87. Kihana T, et al : Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76 : 72-78, 1995.
PubMed
88. Kim YB, et al : Progestin alone as primary treatment of endometrial carcinoma in premonopausal women. Cancer 79 : 320-327. 1997.
 
89. Kimming R : Case report : Conservative treatment of endometrial cancer permitting subsequent triple preganancy. Gynecol Oncol 58 : 255-257, 1995.
 
90. King SA, et al : Expression and mutational analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 75 : 2700-2705, 1995.
PubMed
91. Kitagawa K, et al : Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1. Int J Cancer 66 : 91-97, 1996.
 
92. Klein G & Klein E : Evolution of tumors and the impact of molecular oncology, Nature 315 : 190-195, 1985.
PubMed
93. Kobayashi K, et al : Mutational analysis of mismatch repair genes. hMLH1 and hMSH2, in sporadic endometrial carcinoma with microsatellite instability. Jpn J Cancer Res 87 : 141-145, 1996.
PubMed
94. Kohler MF, et al : Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52 : 1622-1627, 1992.
PubMed
95. Kurman RJ & Norris HJ : Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 49 : 2547-2559, 1982.
PubMed
96. Kurman RJ, et al : The behavior of endometrial hyperplasia. A longterm study of "untreated" hyperplasia in 170 patients. Cancer 56 : 403-412, 1985.
PubMed
97. Kurose K, et al : Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers : evidence for inactivation of both alles. Jpn J Cancer Res 89 : 842-848, 1998.
 
98. Kyo S, et al : Telomerase activity in human endometrium. Cancer Res 57 : 610-614, 1997.
PubMed
99. Kyo S, et al : Estrogen activates telomerase. Cancer Res 59 : 5917-5921, 1999.
PubMed
100. Kyo S, et al : Sp1 cooperates with c-Myc to activate transcription of human telomerase reverse transcriptase gene. Nucleic Acids Res 28 : 669-677, 2000.
 
101. Kyo S, et al : Telomersae activity in cancer as a diagnostic and therapeutic target. Histol Histopathol 15 : 813-824. 2000.
PubMed
102. Kyo S, et al : Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163 : 2259-2269, 2003.
PubMed
103. Kyo S. et al : Significanse of immunological detection of human telomerase reverse transcriptase : re-evaluation of experssion and localization of human telomerasse reverse transcriptase. Am J Pathol 163 : 859-867, 2003.
 
104. Lagarda H, et al : K-ras mutations in endometrial carcinoma withmicrosatellite instability. J Pathol 193 : 193-199, 2001.
PubMed
105. Lax SF, et al : Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53., Ki-67, estrogen and progesteron receptor expression. Human Pathol 29 : 551-558, 1998.
PubMed
106. Lax SF, et al : The frequency of p53, k-ras mutation and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 88 : 814-824, 2000.
PubMed
107. Lessey BA, et al : Distribution of integrin cell adhesion molecules in endometrial cancer. Am J Pathol 146 : 717-726, 1995.
PubMed
108. Levine RL, et al : PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 58 : 3254-3258, 1998.
PubMed
109. Lim PC, et al : Absence of mutations in DNA mismatch repair genes, hMLH1 and hMSH2 in sporadic endometrial carcinoma with microsatellite instability. Clin Cancer Res 2 : 1907-1911, 1996.
 
110. Lin YC, et al : Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etopside therapy. Gynecol Oncol 58 : 262-265, 1995.
 
111. Lowe MP, et al : Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril 77 : 188- 189, 2002.
 
112. Maida Y, et al : Direct activation of telomerase by EGF through Etsmediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21 : 3071-4079, 2002.
 
113. Maida Y, et al : Is the telomerase assay useful for screening of endometrial lesions? Int J Cancer 100 : 714-718, 2002.
PubMed
114. Major FJ, et al : Prognostic factors in early -stage uterine sarcoma. Cancer 71 : 1702-1709, 1993.
PubMed
115. Mariani A, et al : Prospective review of potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76 : 348-356, 2000.
 
116. Maxwell GL, et al : Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Caner Res 58 : 2500-2503, 1998
 
117. Mirabelli-Primdahl L, et al : β-catenin mutations are specific for colorectal carcinomas with microsatellite insatability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59 : 3346-3351, 1999.
 
118. Miyamaoto S, et al : Changes in E-cadherin associated with cytoplasmic molecules in well and poorly differentiated endometrial cancer. Br J Cancer 83 : 1168-1175, 2000.
 
119. Mutter GL, et al : A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal aendometrial cancers and precancers. Am J Pathol 146 : 501-508, 1995.
 
120. Mutter GL, et al : K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. J Clin Pathol 52 : 257-262, 1999.
 
121. Mutter GL, et al : Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 : 924-931, 2000.
PubMed
122. Nakagawa-Okamura C, et al : Effectiveness of mass screening for endometrial cancer. Acta Cytol 46 : 277-283, 2002.
PubMed
123. Nakashima R, et al : Alteration of p16 and p15 gene in human uterine tumours. Br J Cancer 80 : 458-467, 1999.
PubMed
124. Nayfield SG, et al : Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83 : 1450-1459, 1991.
PubMed
125. Nogales FF, et al : Uterine intravascular leiomyomatosis, an update and report of seven cases. In J Gynecol Pathol 6 : 331-339, 1987.
 
126. Norris HJ & Taylor HB : Mesenchymal tumors of the uterus. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 19 : 755-766, 1996.
 
127. Nowell PC : Molecular events in tumor development. N Engl J Med 319 : 575-577, 1988.
PubMed
128. Obata H, et al : Docetaxel and carboplatin combination chemotherapy for recuurent endometrial cancer. Int J Clin Oncol 8 : 53-55, 2003.
 
129. Obata I, et al : Lymphadenectomy and adjuvant therapy in endometrial carcinoma : role of adjuvant chemotherapy. Br J Cancer 87 : 377-380, 2002.
 
130. Obermair A, et al : Prognostic significance of thumor angiogenesis in endometrial cancer. Obstet Gynecol 93 : 367-371, 1999.
 
131. Omura GA, et al : A randomized clinical trial of adjuvant adriamycin in uterine sarcoma. J Clin Oncol 3 : 1240-245, 1985.
PubMed
132. Onda T, et al : Treatment of node dissection, chemotherapy, and radiation therapy. Br J Cancer 75 : 1836-1841, 1997.
PubMed
133. Otsuka I, et al : Lymphadenectomy and adjuvant therapy in endometrial carcinoma. role of adjuvant chemotherapy. Br J Cancer 87 : 377-380, 2002.
PubMed
134. Ozaki K, et al : Fhit alterations in endometrial carinoma and hyperplasia. Int J Cancer 85 : 306-312, 2000.
 
135. Parslov M, et al : Risk factors among young women with endometrial cancer : a Danish case-control study. Am J Obstet Gynecol 182 : 23-29, 2000.
PubMed
136. Peter TR, et al : Cisplatin and adriamycine combination chemotherapy for uterine stromal sarcoma and mixed mesodermal tumor. Gynecol Oncol 23 : 323-327, 1989.
 
137. Peyssonnaux C, et al : The Raf/MEK/ERK pathway : new concepts of activation. Biol Cell 93 : 53-62, 2001.
PubMed
138. Powles TJ & Hickish T : Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst 87 : 1343-1344, 1995.
 
139. Quade BJ, et al : Disseminated peritoneal leiomyomatosis : Clonal analysis by X chromosome inactivation and cytologenetics of a clinically benign smooth muscle proliferation. Am J Pathol 150 : 2153-2166, 1997.
PubMed
140. Quinlivan JA, et al : Accuracy of frozen section for the operative management of endometrial cancer. Br J Obstet Gynecol 108 : 798-803, 2001.
 
141. Randall T, et al : Whole abdominal radiotherapy versus combination chemotherapy with Doxorubicin and Cisplatin in advanced endometrial carcinoma. (phase III) GOG study. No.122. J Natl Cancer Inst Monogr 19 : 13-15, 1995.
 
142. Randall T & Kurman RJ : Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90 : 434-440, 1997.
PubMed
143. Randall ME, et al : Randomized phase III trial of whole abdominal irradiation Versus doxorubicin and cisplatin and cisplatin chemotherapy in advanced endometrial carcinoma. A GOLG study. J Clin Oncol 24 : 36-44, 2006.
 
144. Risinger JI, et al : PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4 : 3005-3010, 1994.
 
145. Risinger JI, et al : PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57 : 4736-4738, 1997.
PubMed
146. Ronett BM, et al : DCCgenetic alterations and expression in endometrial carcinoma. Mod Pathol 10 : 38-46, 1997.
 
147. Rose P, et al : A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma : a GOG study. Gynecol Oncol 78 : 212-216, 2000.
PubMed
148. Rose PG : Endometrial carcinoma. N Engl J Med 335 : 640-649, 1997.
 
149. Saegusa M, et al : β-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84 : 209-217, 2001.
 
150. Saitoh M, et al : Intravenous leiomyomatosis with cardiac extension. Gynecol Obstet Invest 58 : 168-170, 2004.
PubMed
151. Sakuragi N, et al : Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 79 : 153-158, 1998.
PubMed
152. Sakuragi N, et al : Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 53 : 183-189, 1994.
PubMed
153. Salazar OM, et al : Uterine sarcoma : natural history, treatment and prognosis. Cancer 42 : 1152-1160, 1978.
PubMed
154. Salazar OM, et al : Uterine sarcomas ; analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 42 : 1161-1165, 1978.
PubMed
155. Salvesen HB & Akslen LA : Significance of tumor-associated macrophages, vascular endothelial growth factor and thrombospodin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 84 : 538-543, 1999.
 
156. Salvesen HB, et al : Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6 : 3607-3613, 2000.
 
157. Sasaki H, et al : Mutation of the ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53 : 1906-1910, 1993.
PubMed
158. Sawada M, et al : Clonal analysis of human gynecologic cancers by means of the polymerase chain reaction. Int J Cancer 58 : 492-496, 1994.
PubMed
159. Schammel Dp, et al : Endometrial adenocarcinoma associated with intrauterine pregnancy. Int J Gynecol Pathol 17 : 327-335, 1998.
PubMed
160. Schlosshauer PW, et al : Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 13 : 1066-1071, 2000.
PubMed
161. Schwartz S Jr, et al : Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 59 : 2995-3002, 1999.
PubMed
162. Scully RE, et al : Histological typing of female genital tract tumours. World Health Organization. International Histological Classification of Tumours. 2nd edition, Springer-Verlag, New York, 1994.
 
163. Segawa T, et al : Clinicopathological significance of Fragile Histidine Triad Transcription protein expression in endometrial carcinomas. Clin Cancer Res 6 : 2341-2348, 2000.
PubMed
164. Segawa T, et al : Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res 11 : 2188-2194, 2005.
PubMed
165. Shouz M, et al : Inhibition of in situ expression of aromatase p450 in leiomyoma of the uterus by leuprolon acetate. J Clin Endocrinol Metab 86 : 5405-5411, 2001.
 
166. Silverberg SG, et al : Carcinosarcoma of the uterus. A gynecologic group pathologic study of 203 cases. Int J Gynecol Pathol 9 : 1-19, 1990.
PubMed
167. Simpkin SB, et al : MLH1 promoter methylation and gene silenceing is the primary cause of microsatellite instability in sporadic endometrial cancers. Human Mole Genetics 8 : 661-666, 1999.
 
168. Smith HO, et al : The role of colony-stimulating factor 1 and its receptor in the etiopathologenesis of the endometrial adenocarcinoma. Clin Cancer Res 1 : 313-325, 1995.
PubMed
169. Son K, et al : Diagnosis of carcinogenetic potentiality in endometrial precancerous lesions by the clonal analysis. The procced of 52th meeting of Jpn Assoc Obstet Gynecol. (Abstract) Tokushima, Japan, 2000.
 
170. Sumitani H, et al : In situ estrogen synthesized by aromatase p450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinol 141 : 3852-3861, 2000.
 
171. Sutton G, et al : Isofamide and Doxorubicin in the treatment of advanced leiomyosarcomas of the uterus. Gynecol Oncol 62 : 226-229, 1996.
 
172. Sutton G, et al : Ifosphamide treatment of recurrent or metastatic endometrial stomal sarcomas previously unexposed to chemotherapy. Obstet Gynecol 87 : 747-750, 1996.
 
173. Sutton GP, et al : Phase II trial of ifosfamide and mesa in mixed mesodermal tumors of the uterus. Am J Obstet Gynecol 11 : 309-312, 1989.
 
174. Takakura M, et al : Cloning of human telomerase catelytic subunit (hTERT) gene promoter and identificaiton of proximal core promotor sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59 : 551-557, 1999.
 
175. Takakura M, et al : Function of AP-1in transcription of telomerase reverse transcriptase gene in human and mouse cells. Mol Cell Biol 25 : 8037-8043, 2005.
 
176. Takeshima N, et al : Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion. Obstet Gynecol 88 : 280-282, 1996.
PubMed
177. Takeshima N, et al : Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 70 : 183-187, 1998.
PubMed
178. Tamura M, et al : PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 91 : 1820-1828, 1999.
 
179. Tanaka M, et al : Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium. Am J Pathol 163 : 295-301, 2003.
PubMed
180. Tashiro H, et al : P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150 : 177-185, 1997.
PubMed
181. Tashiro H, et al : Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57 : 3935-3940, 1997.
PubMed
182. Taylor HS, et al : Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA 292 : 104-105, 2004.
 
183. Thibodeau Sn, et al : Altered expression of hMSH2 and hMLH1 in tumors with microsatellite insatablity and genetic alterations in mismatch repair genes. Cancer Res 56 : 4836-4840, 1996.
PubMed
184. Thigpen JT, et al : A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma : a GOG study. J Clin Oncol 12 : 1408-1414, 1994.
PubMed
185. Thigpen JT, et al : Phase II trial of cisplatin as a first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma : a GOG study. Gynecol Oncol 33 : 68-70, 1989.
 
186. Thigpen JT, et al : PHase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma : a GOG study Cancer Treatment Rep Rep 63 : 21-27, 1979.
 
187. Tomlinson IP, et al : Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet 30 : 352-353, 2002.
 
188. Ueda G, et al : Argyrophil cell adenocarcinoma of the endometrium. Gynecol Oncol 6 : 467-473, 1978.
PubMed
189. Ueno H, et al : Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 84 : 470-477, 1999.
PubMed
190. Vaccarello L, et al : Endometrial carcinoma associated with pregnancy. A report of three cases and review of the literature. Gynecol Oncol 74 : 118-122, 1999.
PubMed
191. Walker Cl : Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res 57 : 277-294, 2002.
PubMed
192. Wang Z, et al : Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res 60 : 5376-5381, 2000.
PubMed
193. Wang Z, et al : Tamoxifen regulates human telomerase reverse transcriptase gene expression differently in breast breast and endometrial cancer cells. Oncogene 21 : 3517-3524, 2002.
PubMed
194. Yoshinaga K, et al : The PTEN, Bax and IGFIIR genes are mutated in endometrial atypical hyperplasia. Jpn J Cancer Res 89 : 985-990, 1998.
PubMed

第5章 卵巣の疾患

P.155 掲載の参考文献
1. 浅田弘法ほか : PCOSにおける腹腔鏡下手術の応用. 産と婦 70 : 204-211, 2003.
Medical*Online
2. 井上正樹ほか : カルチノイド症候群を呈した卵巣島状カルチノイド腫瘍の 一例. 癌の臨床 24 : 642-648, 1978.
 
3. 蒲田敏文ほか : 卵巣腫瘤MRI信号から何がわかるか. 産婦治療 89 : 105-115, 2004.
 
4. 黒岩哲生 : 婦人科がんの疫学特性. 日産婦誌 55 : 943-951, 2003.
 
5. Ahmed FY, et al : Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14 : 2968-2975, 1996.
 
6. Aida H, et al : Clinical feature of ovarian cancer in Japanese women with germ-line mutation of BRCA 1. Clin Cancer Res 4 : 235-240, 1998.
 
7. Al-Haji M, et al : Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad Sci USA 100 : 3983-3988, 2003.
 
8. Albeits. DS, et al : Intraperitoneal cisplatin plus intravenous cyclophosphamide verus intravenous cisplatin plus intravenous cyclopholphamide for stage III ovarian cancer. N Eng J Med 335 : 1950-1955, 1996.
 
9. Albelt, DS, et al : Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide : Southwest Oncology Group of a phase III randomized trial in stage III and IV suboptimal ovarian cancer. Current Perspectives and Future Directions, pp163-164, WB Saunders, Philadelphia, 1990.
 
10. Axe SR Choroicarcinoma of the ovary. Obstet Gynecol 66 : 111-114, 1985.
PubMed
11. Bajorin DF, et al : Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors. J Clin Oncol 11 : 598-606, 1993.
PubMed
12. Benjamin I, et al : Occult bilateral invovement in stage I epithelial ovarian cancer. Gynecol Oncol 72 : 288-291, 1999.
 
13. Bingham C, et al : The role of the molecular biology in understandin ovarian cancer initiation and progression. Int J Gynecol Cancer 11 (Supple). 7-11, 2001.
 
14. Bonazzi C, et al : Pure ovarian immature teratoma : A unique and curable disease : 10 year's experience of cases prospective treated patients. Obstet Gynecol 84 : 598-604, 1994.
 
15. Calvert AH, et al : Calboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 : 1748-1756, 1989.
 
16. Chalvardjian A & Scullr RE : The Sclerosing stromal tumors of the ovary. Cancer 31 : 664-670, 1973
 
17. Chang S, Risch HA : Perineal talc exposure and risk of ovarian carcinoma. Cancer 79 : 2396-2401, 1997.
PubMed
18. Colombo N, et al : Controversial and issue in the management of early epithelial ovarian carcinoma : conservative surgery and role of adjuvant therapy. Gynecol Oncol 55 : S47-S51, 1994.
 
19. Couch FJ, et al : BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336 : 1409-1415, 1997.
PubMed
20. Cramer DW, et al : Characteristics of women with a family history of ovarian cancer I. Galacose consuption and metabolism. Cancer 74 : 1309-1317, 1994.
 
21. Creasman WT & Soper JT : Assesment of contemporary management of germ cell malignanies of the ovary. Am J Obstet Gynecol 153 : 828-834, 1985.
 
22. Cronje HS, et al : Review of the granulose-theca cell tumors of the Emile Novak ovarian tumor registry. Am J Obstet Gynecol 180 : 323-327, 1999
 
23. Cuatrecasas M, et al : K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 79 : 1581-1586, 1997.
PubMed
24. Dahlgren E, et al : Women with polycystic ovary syndrome wedge resected in 1956 to 1965 : a long term follw-up focusing on natural history and circulating hormones. Fertil steril 57 : 505-513, 1992.
 
25. Daya D : Malignant female adnexal tumor of probable wolffian origin with review of the literature. Arch Pathol Lab Med 118 : 310-312, 1994.
PubMed
26. Dean M, et al : Tumor stem cells and drug resistance. Nature Review Cancer 5 : 275-284, 2005.
 
27. Deborah K, et al : Intraepithelial cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 : 34-43, 2006.
 
28. Dunaif A : Insulin resitence in polycystic ovary syndrome. Ann NY Aca Sci 687 : 60-64, 1993.
 
29. Evans AT, et al : Clinocopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 55 : 231-238, 1980.
 
30. Feeley KM & Well M : Precursor lesions of ovarian epithelial malignancy. Histopathol 38 : 87-95, 2001.
 
31. Fishman A, et al : Leuprolide acetate for treating refractory or persis tent ovarian granulose cell tumor. J Reprod Med 41 : 393-396, 1996.
PubMed
32. Fujita M, et al : Genetic alterations in ovarian carcinoma with specific reference to hitological subtypes. Mol Cell Endocrinol 202 : 97-99, 2003.
 
33. Fujita M, et al : Retrospective review of 41 patients with endodermal sinu stumor of the ovary. Int J Gynecol Cancer 3 : 329-335, 1993.
 
34. Fujita M, et al : Application of clonal analysis ; differential diagnosis for synchronous primary ovarian and endometrial cancer and metastatic cancer. Am J Clin Pathol 105 : 350-359, 1996.
PubMed
35. Gershensen DM : Management of early ovarian cancer : Germ cell and sex cord-stromal tumors. Gynecol Oncol 55 : S62-72, 1994.
 
36. Gonzalez A, et al : Specific CAPN 10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 88 : 5529-5536, 2003.
 
37. Gordon JS, et al : Use of CA-125 to define progression of ovarian cancer in patients with persistly elevated levels. J Clin Oncol 19 : 4054-4057, 2001.
 
38. Gotlieb WH, et al : Borderline tumors of the ovary : fertility treatment conservative management and pregnancy outcome. Cancer 82 : 141-146, 1998.
PubMed
39. Gras E, et al : Microsatellite instability, MLH-1 promoter hypermethylation and frame-shift mutations at the coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92 : 2829-2836, 2001.
PubMed
40. Gu J, et al : Molecular evidence for the independent origin of extraovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 93 : 1147-1152, 2001.
PubMed
41. Guthrie D, et al : A sutdy of 656 patients with early ovarian cancer. Gynecol Oncol 17 : 363-369, 1984.
 
42. Hemminki A, et al : A serine/threonine kinase gene defective in Peutz-Jegher sybdrome. Nature 391 : 184-187, 1998.
 
43. Homesley HD, et al : Bleomycin, etopside and cisplatin comination therapy of ovaroian granulose cell tumors and other stromal malignancies : a gynecologic Group stidy. Gynecol Oncol 72 : 131-137, 1999.
 
44. Hoskins WJ, et al : The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual ovarian carcinoma. Am J Obstet Gynecol 170 : 974-979, 1994.
PubMed
45. Hryniuk W & Levine MN : Analysis of dose intensity for adjuvant chemotherapy trials instage II breast cancer. J Clin Oncol 4 : 1163-1170, 1986.
 
46. Inoue M, et al : Benign cystic teratoma of the ovary containing a homunculus. Acta Obstet Gynecol Jpn 37 : 1050-1053, 1985.
 
48. Inoue M, et al : Histogenetic analysis of ovarian germ cell tumors by DNA fingerprinting. Cancer Res 52 : 6823-6826, 1992.
PubMed
49. Inoue M, et al : STM, SLX, CA19-9, CA125, CEA, and TPA in differentiating ovarian cancer from benign tumors. Obstet Gynecol 79 : 434-440, 1992.
 
50. Inoue M, et al : Long-term follow-up of patients with advanced ovarian ancers treated with intermittent administration of combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Int J Gynecol Cancer5 : 374-380, 1995.
 
51. Ishikura H & Scully RE : Hepatoid carcinoma of the ovary : A newly described tumor. Cancer 60 : 2775-2784, 1987.
PubMed
52. Jacobs IJ, et al : Screening for ovariall cancer : a pilot randomized controlled trial. Lancet 353 : 1207-1210, 1999.
 
53. Jorgensen N, et al : Heterogeneity of gonadoblastoma germ cells ; similarities with immaturc germ cells, spermatogonia and testicular carcinoma in situ cells. Histopathol 30 : 177-186, 1997.
 
54. Joseph H, et al : Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42 : 146-150, 1991.
 
55. Katabuchi H, et al : Micropapillary serous carcinoma of the ovary : an immunohistochemical and mutation analysis of p53. In J Gynecol Pathol 17 : 54-60, 1998.
 
56. Kennedy AW, et al : Ovarian papillary serous tumors of low malignant potential. A long-term follow up study, including patients with microinvasion, lymph node metastasis and transformation to invasive serous carcinoma. Cancer 78 : 278-286, 1996.
PubMed
57. Kimura T, et al : Use of serum TA-4 in monitering patients with malignant transformation of ovarian mature cystic teratoma. Cancer 64 : 480-483, 1989.
 
58. King MC, et al : Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 : National adjuvant breast and bowel project (NSABP-P1) breast cancer preven-tion trial. JAMA 286 : 2251-2256, 2001.
 
59. Komata T, et al : Treatment ofmalignant glioma cells with the transfer of constitutively active caspasc-6 using the human telomerase catalytic subnuit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61 : 5796-5802, 2001.
 
60. Kuhn W, et al : Neoajuvant chemotherapy followed by tumordebulking prolongs survival for patient with poor prognosis in FIGO stage IIIc ovarian carcinoma. Cancer 92 : 2585-2591, 2001.
 
61. Kurman RJ & Norris HJ : Malignant germ cell tumors of the ovary. Human Pathol 8 : 551-564, 1977.
PubMed
62. Kuroda H, et al : Human chorionic gonadotrophin inhibits cisplatin-induced apoptosis in ovarian cancer cells. Int J Cancer 76 : 571-578, 1998.
PubMed
63. Kyo S & Inoue M : Complex regulatory mechanisms of telomerase activity in normal and cancer cells : how can we apply them for cancer therapy? Oncogene 21 : 688-697, 2002.
PubMed
64. Lacey JV Jr, et al : Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 : 334-341, 2002.
PubMed
65. Lapidot T, et al : A cell initiating human acute myeloid leukemia after transcription into SCID mice. Nature 367 : 645-648, 1994.
 
66. Lappohn RE, et al : Inhibin as a marker for granulosc ccll tumors. NEngl J Med 321 : 790-793, 1989.
 
67. Lathrop JC : Malignant pelvic lymphoma. Obstet Gynecol 30 : 137-145, 1967.
PubMed
68. Loehrer PJ, et al : Salvage therapy in recurrent germ cell canceer - ifosfamide and cisplatin plus either vinblastin or etoposide. Ann Intern Med 109 : 540-546, 1988.
PubMed
69. Lynch HT, et al : An update on DNA-based BRCA1/BRCA2 genetic counseling inhereditary brcast cancer. Cancer Genet Cytogenet 109 : 91-98, 1999.
 
70. Lynch HT, et al : Genetics and ovarian carcinoma. Semi Oncol 25 : 2665-2680, 1998.
 
71. Mandai M, et al : Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special referencc to histopathology. Hum Pathol 29 : 34-40, 1998.
PubMed
72. Markman M, et al : Phase III randomized trial of 12 months vs 3 month of pachtaxel hl patients with advanced ovarian, tubal, and primary peritoneal cancer who attain a clinically defined CR following TP chemotherapy. 2002 GOG statistical report.
 
73. Markman M, et al : Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma. J Clin Oncol 19 : 1001-1007, 2001.
 
74. Matsui Y, et al : Embryonic expression of a haematopoetic growth factor encoded by the SI locus and the ligand for c-kit. Nature 347 : 667-669, 1990.
 
75. McCluggage WG & Maxwell P : Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathol 38 : 403-408, 2001.
 
76. McCluggage WG, et al : Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin. Human Pathol 28 : 1034-1038, 1997.
PubMed
77. McGuire WP, et al : Cyclophosphamide and cisplatin compared with paclitaxicel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334 : 1-6, 1996.
 
78. Mok SC, et al : Mutation of K-ras protooncogene in human ovarian epithelial tumors of the borderline malignancy. Cancer Res 53 : 1489-1492, 1993.
PubMed
79. Monterroso V, et al : Malignant lymphomas involving the ovary. A Clinicopathologic analysis of 39 cases. Am J Surg Pathol 17 : 154-170, 1993.
PubMed
80. Morice P, et al : Results of conscrvative treatinent in epithelial ovarian carcinoma. Cancer 92 : 2412-2418, 2001.
 
81. Muggia FM, et al : Phase III randomized study of cisplatin versus placlitaxel versus cisplatin and paclitaxel in patients with suboptilnal stage IIIor IV ovarian cancer. A Gynecologic Oncology study. J Clin Oncol 18 : 106-115, 2000.
 
82. Nakajima M, et al : Genetic polymorphisms of CYP2C8 in Japancse population. Drug Metab Dispos 31 : 687-690, 2003.
PubMed
83. Nakamura M, et al : Isolation, growth and characteristics of human ovarian surface epithelium. Virchow Arch 424 : 59-67, 1994.
PubMed
84. Neijt JP, et al : Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18 : 3084, 2000.
PubMed
85. Nezhat F, et al : Four ovarian cancers diagnosed during laparoscopic management of 1011 women with adnexal mass. Am J Obstet Gynecol 167 : 790-796, 1992.
 
86. Nicoletto MO, et al : Surgical second look in ovarian cimcer. A randomized study in patients with laparoscopic complete resection. A Northeastem Oncology group. J Clin Oncol 15 : 994-999, 1997.
 
87. Nicosia SV, et al : Gonadal effects of cancer therapy in girls. Cancer 55 : 2364-2372, 1985.
PubMed
88. Nitta M, et al : Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol 81 : 10-17, 2001.
PubMed
89. Obata K, et al : Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 : 2095-2097, 1998.
PubMed
90. Ovalle F & Azziz R : Insuhn resistance, polycystic ovarian syndrome and type 2 diabetes mellitus. Fertil Steril 77 : 1095-1105, 2002.
PubMed
91. Ovarain Cancer Meta-analysis Project : Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma : a meta-analysis. J Clin Oncol 9 : 1668-1674, 1991.
 
92. Ozols RF, et al : Phase III trial of carboplatin and paclitaxcl compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : Gyneologic oncology group study. J Clin Oncol 21 : 3194-3200, 2003.
 
93. Ozols RF : Ovarian Cancer. Atlas of Clinical Oncology, BC Decker Inc, 2003.
 
94. Palacios J, et al : Mutations in the beta-catenin gene in endometri oid ovarian carvoinomas. Cancer Res 58 : 1344-1347, 1998.
 
95. Peterson WF, et al : Benign cystic teratomas ofthe ovary. A clinicopathological study of 1007 cases with review of the literature. Am J Obstet Gynecol 70 : 368-382, 1955.
 
96. Petterson F, et al : Annual report on the results of treatment in gynecological cancer. FIGO, Stockholm, 1991.
 
97. Purdie DM, et al : Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104 : 228-232, 2003.
PubMed
98. Redman CW, et al : Intervcntion debulkiong surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 101 : 142-146, 1994.
PubMed
99. Rey RA, et al : Antimullerian hormones as a serum markcr of granulose cell tumors of the ovary. Comparative study with serum alpha inhibin and estradioL Am J Obstet Gynccol 174 : 958-965, 1996.
 
100. Riccart MJ, et al : Randomizcd intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophobphamide in women with advanced epithelial ovarian cancer : three year result. J Natl Cancer Inst 92 : 699-708, 2000.
 
101. Rice BF, et al : Luteoma of pregnancy. Steroidgenic and morphologic considerations. Am J Obstet Gynecol 104 : 871-878, 1969.
 
102. Riman T, et al : Hormone replacement therapy and the risk of invasive epithelial oavarian cancer in Swedish women. J Natl Cancer Inst 94 : 497-504, 2002.
PubMed
103. Rishi M, et al : Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 21 : 583-589, 1997.
PubMed
104. Robboy SJ & Scully RE : Ovarian teratoma with glial implants on the peritoneum. Human Pathol 1 : 643-653, 1970.
PubMed
105. Robboy SJ & Scully RE : Strumal carcinoid of the ovary : An analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer 46 : 2019-2034, 1980.
PubMed
106. Rose PG, et al : Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 : 2489-2497, 2004.
PubMed
107. Rose PG : Second line therapy with paclitaxel and carboplatin for recurrent disease following first-line Therapy with paclitaxel and platinum in ovarian or peritoneal carchloma. J Clin Oncol 16 : 1494-1497, 1998.
PubMed
108. Rossing MA, et al : Ovarian tumors in a cohort of infertile women. N Eng J Med 331 : 771-776, 1994.
 
109. Russell P : The pathological assesslnent of ovarian neoplasms. III : The malignant "epithclial" tumours. Pathol 11 : 493-532, 1979.
 
110. Sakuragi N, et al : Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limitcd to the pelvis. Gynecol Oncol 79 : 251-255, 2000.
 
111. Sato S, et al : Usefulness of mass screening for ovarian cancer using transvaginal ultrasonography. Cancer 89 : 582-588, 2000.
PubMed
112. Schumer ST & Cannistra SA : Granulosa cell tumor of the ovary. J Clin Oncol 21 : 1180-1189, 2003.
PubMed
113. Schwartz PE & Smith JP : Treatment of ovarian stromal tumors. Am J Obstet Gynecol 125 : 402-408, 1976.
PubMed
114. Schwartz PE, et al : Ovarian germ cell malignancies. Gynecol Oncol 45 : 26-31, 1992.
PubMed
115. Scully RE : Gonadoblustoma. A review of 74 cases. Cancer 25 : 1340-1356, 1970.
PubMed
116. Scully RE : Sex cord tumor with annual tubules a distinctive ovarian tumor of the Peutz-Jegher syndrome. Cancer 25 : 1107-1121, 1970.
 
117. Shinozuka T, et al : High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian carinoma. Cancer 85 : 1555-1564, 1999.
 
118. Shozu M, et al : Leak-proof pumcture of ovarian cysts : Instant mounting of plastic bag using cyanoacrylate adhesive. Obstet Gynecol 96 : 1007-1010, 2001.
 
119. Sjovall K, et al : Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer 4 : 333-336, 1994.
PubMed
120. Stein IF & Leventhal ML : Amenorrhea associated with bilateral polycystic ovarics. Am J Obstet Gynecol 29 : 181-191, 1935.
 
121. Stenwig JT, et al : Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 7 : 136-152, 1979.
PubMed
122. Taki M, et al : Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 24 : 3130-3140, 2005.
PubMed
123. Tamini HK & Bolen JW : Enchondromatosis and ovarian granulose cell tumor. Cancer 53 : 1605-1608, 1984.
 
124. Teilum G : Classification of endodermal sinus tumor and so-called embryonal carcinoma of the ovary. Acta Pathol Microbiol Scand 64 : 407-420, 1965.
PubMed
125. The ICON and AGO collaborators : Paclitaxel plus platinum-based chemotherapy verus conventional platinum-based chemotherapy in wopmen with relapsed ovarian cancer, The ICON4/AGO-Ovar-22 trial. Lancet 361 : 2099-2106, 2003.
 
126. The ICON3 Randomized Trial : Paclitaxel plus carboplathl versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer. Lancet 360 : 505-515, 2002.
PubMed
127. Therasse P, et al : New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 : 205-216, 2000.
PubMed
128. Thigpen JT : Dose-intensity in ovarian carcinoma : Hold, enough? J Clin Oncol 15 : 1291-1293, 1997.
PubMed
129. Ulbright TM, et al : Yolk sac differentiation in germ cell tumors. A morphologic study of 50 cascs with emphasis on hepatic, enteric and parietal yolk sac features. Am J Surg Pathol 10 : 151-164, 1986.
 
130. Urbanek M, et al : Thirty-seven candidatc genes for polycystic ovary syndrome. Proc Natl Acad Sci USA 96 : 8573-8578, 1999.
 
131. Van der Burg MEL, et al : The effect of debulking surgcry after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332 : 629-634, 1995.
 
132. Vasey PA : Survival and long-term toxicity results of the SCOTROC study : dotctaxel-carboplatin (DC) vs paclitaxel-carboplatin (PC) in epithelial ovarian cancer. Proc Am, Soc Clin Oncol Abstract, 2002.
 
133. Waterworth DM, et al : Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 349 : 986-990, 1997.
PubMed
134. Williams SD, et al : Treatment ordisseminated germ-cell tumors with cisplatin, bleomycin and either vinblastin or etopside. N Engl J Med 316 : 1435-1440, 1987.
 
135. Yamada Y, et al : Gynandroblastoma of the ovary having a typical morphological appearance. A case study. Jpn J Clin Oncol 21 : 62-68, 1991.
PubMed
136. Young RH & Scully RE : Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 9 : 543-569, 1985.
PubMed
137. Young RH, et al : Small cell carcinoma of the ovary, hypercalcemic type ; A clinicopathological analysis of 150 cases. Am J Surg Pathol 18 : 1102-1116, 1994.
PubMed
138. Young RH & Scully RE : Fibromatosis and massive edema of the ovary, possibly related entities : a report of 14 cases of fibromatosis and 11 cases of massive edema. Int J Gynecol Oncol 3 : 153-178, 1984.
 
139. Young RH, et al : Ovarian endometrioid carcinomasa resemblillg sexcord stromal tumors ; a clinicopathological analysis of 13 cases. Am J Surg Pathol 6 : 513-522, 1982.
 
140. Young RH, et al : Juvenile granulose cell tumor of the ovary. A clinicopathologic analysis of 125 cases. Am J Surg Pathol 8 : 575-596, 1984.
 
141. Young RH & Scully RE : Ovarian Sertoli-Leydig cell tumors with a retiform pattem. A problem in histopathologic diagnosis. A report of 25 cases. Am J Surg Pathol 7 : 755-771, 1983.
 
142. Zanetta G, et al : Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynecol 104 : 1030-1035, 1997.
 
143. Zanetta G, et al : Behavior of borderline tumors with paricular interest to persistence, recurrence and progression to invasive carcinoma : a prospective study. J Clin Oncol 19 : 2658-2664, 2001.
 
47 Inoue M, et al: Coexpression of the c-kit receptor and the stem cell factor in gynecologic tumors. Caner Res 54 : 3049-3053, 1994.
 

第6章 卵管・子宮広間膜・腹膜の腫瘍 - 卵管癌 -

P.229 掲載の参考文献
1. 本山悌一 : 卵管・附属器疾患. 病理と臨床 13 (臨時増刊号) : 329-340, 1995.
 
2. Alvarado-Cabrcro I, et al : Carcinoma of the fallopian tube : a clini copathologic analysis of 105 cases with observations on staging and Prognostic factors. Gynecol Oncol 72 : 367-379, 1999.
 
3. Alvarez A, et al : K-ras mutations in mullerian inclusioncyst associated with serous borderline tumors of the ovary. Gynecol Oncol 80 : 201-206, 2001.
PubMed
4. Aziz S, et al : A genetic cpidemiological study of carcinonla of the fallopian tube. Gyecol Oncol 80 : 341-345, 2001.
 
5. Bandera CA, et al : BTCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 92 : 596-600, 1998.
PubMed
6. Bell DA, et al : Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 62 : 2212-2222, 1988.
PubMed
7. Cohen MA, et al : Hydrosalpinges adversely affects implantation in donor oocyte cycles. Human Reprod 14 : 1087-1089, 1999.
PubMed
8. Creasman WT : Revision in classificatiool by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 167 : 857-858, 1992.
PubMed
9. Denham JW, et al : The mangement of primary carcinoma of the fallopian tube. Cancer 53 : 166-172, 1984.
 
10. Gershenson DM, et al : Serous bordcrline tumors of the ovary with noninvasive peritoneal iniplants. Cancer 83 : 2157-2163, 1998.
PubMed
11. Goldblum JR, et al : Localized and diffuse mesotheliomas of the genital tracd and peritoneum in women. A clinicopathologic study of nineteen true mesothclial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 19 : 1124-1137, 1995.
 
12. Karian BY, et al : Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer. Implication for ovaran cancer screening. Am J Obstet Gynecol 180 : 917-928, 1999.
 
13. Leake JF, et al : Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential.Gynecol Oncol 42 : 124-130, 1991.
PubMed
14. McMurray EH, ct al : Carcinoma of the fallopian tube. Management and sites of failure. Cancer 58 : 2070-2075, 1986.
 
15. Peters WA, et al : Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 71 : 757-762, 1988.
PubMed
16. Quade BJ, et al : Disseminated peritoneal leiomyomatosis : clonality analysis by X chromosome inactivation and cytologics of a clinically benign smooth muscle proliferation. Am J Pathol 150 : 2153-2166, 1997.
 
17. Quddus MR, et al : Comparison on omental endosalpingiosis and endometriosis. Modern Pathol 11 : 112A, 1998.
 
18. Quddus MR, et al : Benign and malignant serous and endometrioid epithelium in the omentum. Gynecol oncol 75 : 227-232, 1999.
PubMed
19. Schorge JO, et al : BRCA-1- related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 60 : 1361-1364, 2000.
 
20. Silva EG, et al : Tumor recurrence in stagc 1 ovarian serous neoplasms of low malignant potential. Int Gynecol Pathol 17 : 1-6, 1998.
PubMed
21. Skjeldestad FE, et al : Multiple induced abortions as risk factor for ectopic pregnancy : a prospectivc study. Acta Obstet Gynecol Scand 76 : 691-696, 1997.
PubMed
22. Tonin P, et al : Linkage analysis of 26 Canadian breast-ovarian cancer families. Human Genet 95 : 545-550, 1995.,
PubMed
23. Weiss SW & Tavassoli FA : Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 12 : 737-746, 1988.
PubMed

第7章 子宮内膜症

P.241 掲載の参考文献
1. 石川睦男ほか : ダイオキシン類の汚染状況および子宮内膜症など健康調査に関する研究. 厚生科学生活安全事業 (平成11-13年度) 報告.
 
2. 小林浩 : 子宮内膜症と癌化-特に卵巣子宮内膜症-. 日医会誌 134 : 415-419, 2005.
 
3. 武谷雄二ほか : リプロダクテイブヘルスからみた子宮内膜症の実態と対策に関する研究. 厚生省班研究報告, 1998.
 
4. Amer Soci for Reprod Med : Revised American society for rcproductive Medicine classification of endometriosis-1996. Fertil Steril 67 : 817-821, 1997.
 
5. Ballouk F, et al : Ovarian endometriotic cysts, An analysis of cytologic atypia and DNA ploidy patterns. Am J Clin Pathol 102 : 415-419, 1994.
PubMed
6. Barnhart K, et al : Effect of endometriosis on in vitro fertilization. Fertil Steril 77 : 1148-1155, 2002.
PubMed
7. Berube S, et al : Charactetistics related to the prevalence cf minimal or mild endometrios is in fertile women. Cannadian Collaborative Group on endometriosis. Epidemiology 9 : 504-510, 1998.
 
8. Brinton LA, et al : Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176 : 572-579, 1997.
PubMed
9. Bulun SE, et al : Estrogen biosynthesis in endometriosis : molecular basis and clinical relevance. J Mol Endocrinol 25 : 35-42, 2000.
PubMed
10. Bulun SE, et ai : Role of aromatase in endometrial tissue. J Steroid Biochem Mol Biol 79 : 19-25, 2001.
 
11. Chapron C, et al : Management of ovarian endometriosis. Human Reprod Up-date 8 : 591-597, 2002.
 
12. Cramer DW, ct al : Thc relation of endometriosis to menstrual characteristics, smoking and excrcise. JAMA 255 : 1904-1908, 1986.
 
13. DePriest PD, et al : Endometrioid carcinoma of the ovary and endometriosis. Gyncol Oncol 47 : 71-75, 1992.
 
14. Diag I, et al : Impact of stage III/IV endometriosis on recipients of sibling oocytes. Matched case. control study. Fetil Steril 74 : 31-34, 2000.
 
15. Dinulescu DM, et al : Role of K-ras and Pten in the development of mouse niodels of endometriosis and endornetrioid ovarian cancer. Nature Med 11 : 63-70, 2005.
PubMed
16. Donnez J, et al : Retrovaginal septum adenoinyotic nodules : a series of 500 cases. Br J Obstct Gynecol 104 : 1014-1018, 1997.
 
17. Erzen M & Kovacic J : Relationship between endomctriosis and ovarian cancer. Eur J Gynecol Oncol 19 : 553-555, 1998.
 
18. Evers JL : Endoinetriosis does not exist : all women have endometriosis. Human Reprod 9 : 2206-2209, 1994.
 
19. Fang Z, et al : Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. J Clin Endocrinol Metab 87 : 3460-3466, 2002.
 
20. Gazetti GG, ct al : Decrease in pcripheral blood polymorphonuclcar lcukocyte chemotractic index in endometriosis : role of prostagrandin E2 release. Obstct Gynecol 91 : 25-29, 1998.
 
21. Guidice L & Kao L : Endometriosis. Lancet 364 : 1789-1799, 2004.
 
22. Haney AF : Endometriosis-associated infertility. Baillieres Clin Obstet Gynecol 7 : 791-821, 1993.
 
23. Heaps J, et al : Malignant neoplasms arising in endometriosis. Obstet Gynecol 75 : 1023-1025, 1990.
PubMed
24. Henzel MR, et al : The treatment of dysmenorrhea with naproxen sodium. Am J Obst Gynecol 127 : 818-823, 1977.
 
25. Henzl MR, et al : Efficacy and safety of nafarelin in the treatment of endometrios is. Am J Obstet Gynecol 162 : 570-574, 1990.
 
26. Inoue K, et al : The impact of endometriosis on the reproductive outcome of infertile patients. Am J Obstet Gynecol 167 : 278-282, 1992.
 
27. Jiang X, et al : Micosatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 56 : 3534-3539, 1996.
 
28. Jiang X, et al : Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58 : 1707-1712, 1998.
PubMed
29. Jones KD : Pregnancy rates following ablative laparoscopic surgery for endometriosis. Human Reprod 17 : 782-785, 2002.
PubMed
30. Joseph J et al : Thoracic endometriosis syndrome : new observation from an analysis of 110 cases. Am J Med 100 : 164-170, 1996.
PubMed
31. Kirson B, et al : Contraception : a risk factor for endomctriosis. Obstct Gynecol 71 : 829-831, 1988.
 
32. Komiyama S, et al : Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endomctriosis : clinicopathologic evaluation. Gynecol Oncol 72 : 342-346, 1999.
PubMed
33. Koninckx PR, et al : Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 55 : 759-765, 1991.
PubMed
34. Lauchian SC : The secondary mullerian system. Obstet Gynecol Surv 27 : 133-146, 1972.
 
35. Marcoux S, et al : Laparoscopic surgery in infertile women with minimal on mild endometriosis. N Eng J Med 337 : 217-222, 1997.
 
36. Moen MH, et al : The familial risk of endometriosis. Acta Obstet Gynccol Scand 72 : 560-564, 1993.
PubMed
37. Noble LS, et al : Aromatase expression in endometriosis. J Clin Endocrinol Metab 81 : 174-179, 1996.
PubMed
38. Nomura K, et al : Local application of danazole-loaded hyaluronic acid hydrogel to endometriosis in a rat model. Fertil Steril 2006.
 
39. Obata K, et al : Frequent PTEN/MMA mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 : 2095-2097, 1998.
PubMed
40. Ohno S, et al : Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25 : 3679-3688, 2005.
PubMed
41. Ranney B : Endometriosis. IV. Hereditary tendency. Obstet Gynecol 37 : 734-737, 1971.
PubMed
42. Sampson JA : Perforating hemorrhagic cysts of the ovary ; their importance and especially their relation to pelvic adenomas of endometrial type. Arch Surg 3 : 245-323, 1921.
 
43. Sampson JA : Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg 10 : 1-72, 1925.
 
44. Shaw RW, et al : Nafarelin in the treatment of pelvic pain by endometriosis. Am J Obstet Gynecol 162 : 574-576, 1990.
PubMed
45. Shozu M, et al : A new case of female pseudohenmaphorism : Placental aromatase deficiency. J Clin Endocrinol Metab 72 : 560-566, 1991.
PubMed
46. Shozu M, et al : Multiple splicing events involved in regulation of human aromatase expression by a novel promoter 1.6. Endocrinol 139 : 1610-1617, 1998.
 
47. Stern RC, et al : Malignancy in endometriosis : frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20 : 133-139, 2001.
PubMed
48. Takayama K, et al : Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69 : 709-713, 1998.
PubMed
49. Tamura M, et al : Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalinfixed, paraffin-embedded tissue. Lab Invest 78 : 213-218, 1998.
PubMed
50. Vercellini P, et al : A gonadotrophin-releasing hormone agonist versus a low dose oral contraceptivr for endometriosis associated dysmenorrhea that does not respond to a cycle pill regimen. Fertil Steril 80 : 560-563, 2003.
PubMed
51. Vessey MP, et al : Epidemiology of endometriosis in women attending family planning clinics. Br Med J 306 : 182-184, 1993.
 
52. Yang HJ, et al : Spatially heterogeneous expression of aromatase P450 through promoter II is closely correlated with the level of steroidgenic factor-1 transcript in endometrioma tissue. J Clin Endocrinol Metab 87 : 3745-3753, 2002.
 
53. Yoshikawa H, et al : Pevalance of endometriosis in ovarian cancer. Gynecol Obstet Invest 1 : 11-17, 2000.
 
54. Zeitoun KM & Bulun SE : Aromatase : a key molecule in the pathophysiology of endometriosi and a therapeutic target. Fertil Steril 72 : 961-969, 1999.
 

第8章 妊娠性絨毛性疾患

P.251 掲載の参考文献
1. Bowea M, et al : EMA/CO for high-risk gestational trophoblastic tumors. Result from a cohort of 272 patients. J Clin Oncol 15 : 2636-2643, 1997.
PubMed
2. Curry SL, et al : A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclopsphamde, doxorubicin, melphalan, hydroxyurea and vincristine in "Poor prognosis" metastastic gestational trophoblastic disease : a GOG study. Obstet Gynecol 73 : 357-362 1989.
 
3. FIGO Oncology Committee Report : FIGO staging for gestational trophoblastic neoplasia 2000. Int J Obstet 77 : 285-287, 2002.
 
4. Kajii T, et al : Androgenic origin of hydatidiform mole. Nature 268 : 633-634, 1977.
 
5. Lurain JR : Management of high-risk gestational trophoblastic disease. J Reprod Med 43 : 44-52, 1998.
PubMed
6. Lurian JR : Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med 47 : 451-459, 2002.
 
7. Matsui H, et al : Combination chemotherapy with methotrexate, etopside, and actinomycin D for high-risk gestational trophoblastgic tumors. Gynecol Oncol 78 : 28-31, 2000.
 
8. Newlands ES, et al : Management of placental site trophoblastic tumors. J Reprod Med 43 : 53-59, 1998.
PubMed
9. Newlands ES, et al : Etoposide and cisplatin/etoposide, methotrexate, and actinomycine D (EMA) chemotherapy for patients with high-risk gestational trophoblaslic tumors refractory to metastatic placental site trophoblastic tumors. J Clin Oncol 18 : 854-859, 2000.
PubMed
10. Ngan HYS : Thc practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 14 : 202-205, 2004.
 
11. Pedro F, et al : Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine chemotherapy. Gynecol Oncol 91 : 552-557, 2003.
 
12. Schink TJ, et al : Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine for thc treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 80 : 817-820, 1992.
 
13. Scully RE & Young RH : Trophoblastic pseudotumor. Am J Surg Pathol 5 : 75-76, 1981.
PubMed
14. Shozu M, et al : Hydatidiform moles associated with multiple gestations after assisted reproduction. Diagnosis by analysis of DNA fingerprint. Hum Reprod 4 : 877-880, 1998.
PubMed
15. Young RH, et al : Placental site nodules and plaques : A clinicopathologic analysis of 20 cases. Am J Surg Pathol 14 : 1001-1009, 1990.
PubMed

第9章 性器感染症とその関連病変

P.261 掲載の参考文献
1. 大滝倫子 : シラミの防除と治療. 日本医事新報 No.4085 : 33-36, 2002.
 
2. 新付直人ほか : 性感染症診断・治療ガイドライン 2004. 日性感染学会誌 15 (Suppl) : 2004.
 
3. 日産婦医会編 : 感染とパートナーシップ. 研修ノート 69, 2002.
 
4. Enright AM, et al : Neonatal herpes infection : diagnosis, treatment and prevention. Seminor Neonatol 7 : 283-291, 2002.
 
5. Franchini M, et al : Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J Virol 75 : 83-89, 2001.
PubMed
6. Fujita M, et al : Alteration of the p53 gene in human primary ccdrvical carcinoma with and without human papillomavirlls infection. Cancer Res 52 : 5323-5328, 1992.
PubMed
7. Inoue M, et al : Human papillomavirus type 16 in semen of partners of women with HPV infection. The Lancet 339 (i) : 1114-1115. 1992.
 
8. Peopert JF, et al : Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol 117 : 1184-1187, 1997.
 
9. Renzi C, ct al : Herpcs simplex virus type 2 infection as a risk factor for human immunodcficiency virus acquisition in men who havec sex with men. J Infec Dis 187 : 19-25, 2003.
 
10. Rooney JF, et al : Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 314 : 1561-1564, 1986.
PubMed
11. Sasagawa T, et al : High. risk and multiple human papillomavirus infections associated with ccrvical abnormalities in Japnese women. Cancer Epidemiol Biomarker Prevent 14 : 75-92, 2004
 
12. Sasagawa T, et al : Induction of uterine cervical neoplasias in mice by human papillomavirus type 16E6/E7 genes. Cancer Res 52 : 4420-4426, 1992.
 
13. Skinner RB Jr : Imiquimod. Dermatol Clin 21 : 291-300, 2003.
PubMed
14. Wehbeh HA, et al : Single dose azithromycin for chlamydia in pregnant women. J Peprod Med 43 : 509-514, 1998.
PubMed

第10章 遺伝性 ( 家族性 ) 癌症候群

P.269 掲載の参考文献
1. 牛尾恭輔ほか : Cowden病の病態とPTEN遺伝子. 遺伝子医学 3 : 459-465. 1999.
 
2. 土屋敦雄ほか : 家族性乳癌. 阿部力哉 (編). pp17-20, 篠原出版, 東京, 1996.
 
3. 野水整ほか : 家族性乳癌. 宇都宮謙二 (監修), Molecular Med (別冊), pp198-204, 1998.
 
4. Aida H, et al : Clinical feature of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4 : 235-240, 1998.
PubMed
5. Berchuck A. et al : Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Can Res 4 : 2433-2437, 1998.
PubMed
6. Berends MJW, et al : Molecular and clinical characteristics of MSH6 variants : An analysis of 25 index carriers of a germline variant. Am J Hum Genet 70 : 26-37, 2002.
PubMed
7. Enomoto T, et al : Alterations of the P53 tumor suppressor gene and its association with Activation of c-Kras 2 protooncogene in malignant and malignant lesions of the human uterine endomctrium. Cancer Res 53 : 1883-1888, 1993.
PubMed
8. Enomoto T, et al : Alteeration of the tumor suppressor gene and activation of the c-Kras 2 protooncogene in endometria adenocarcinoma from Colorado. Am J Clin Pathol 103 : 224-230, 1995.
 
9. Esteller M, et al : hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155 : 1767-1772, 1999.
PubMed
10. Hemminki A, et al : Scrine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391 : 184-187, 1998.
 
11. Inoue M, et al : Immunohistochemical analysis of p53 in gynecologic cancer. Am J Clin Pathol 102 : 665-670, 1994.
PubMed
12. Inoue M : Current Molecular aspect of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 11 : 339-348, 2001.
PubMed
13. Jegher H, et al : Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. A syndrome diagnostic significance. N Engl J Mcd 241 : 992-1005, 1031-1036, 1949.
 
14. Jenne D, et al : Peutz-Jegher syndrome is caused by mutations in a novel serine threonine kinasc. Namre Genet 18 : 38-43, 1998.
 
15. Kanaya T, et al : Association of mismatch rcpairdefiency with PTEN frameshift mutations in endolnetrial cancers and the precursors in a Japanese population. Am J Clin Pathol 124 : 1-8, 2005.
 
16. Kanaya T, et al : Frequent hypermethylation of hMLH1 promoter in normal endometrium of patientswith endometrial cancers. Oncogene 22 : 2352-2360, 2003.
 
17. Katabuchi K, et al : Mutations in DNA mismatch repair genes are not responsive for microsatellite instability in sporadic endometrial tumors. Cancer Res 55 : 5556-5560, 1995.
 
18. Kundson AG : Antioncogene and human cancer. Proc Natle Acad Sci USA 90 : 10914-10921, 1983.
 
19. Kolodner RD, et al : Structure of the human MSH2 locus and analysis of two Muir-Torre Kindreds for MSH2 mutations. Genomics 24 : 516-526, 1994.
PubMed
20. Li FP & Fraumeni JF Jr : Soft tissue sarcoma, breast cancer and other neoplasm : A familiar syndrome? Ann Intern Med 71 : 745-752, 1969.
 
22. Miki Y, et al : A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 : 66-71, 1994.
 
23. Narod SA, et al : Oral contraceptives and the risk of hereditary ovarian cancers. Hereditary ovarian cancer cinical study group. N Engl J Med 139 : 424-428, 1998.
 
24. Noguchi S, et al : Clinicopathologic analysis of BRCA1 or BRCA2 associated hereditary breast carcinoma in Japanese women. Cancer 85 : 2200-2205, 1999.
 
25. Pharoah PD, et al : Survival in familial BRCA1 associated, and BRCA2 associated epithelial ovarian cancer. Cancer Res 59 : 868-871, 1999.
PubMed
26. Tamura M, et al : PTEN gene and integrin signaling in cancers. J Natl Cancer Inst 91 : 1820-1828, 1999.
PubMed
27. Tashiro H, et al : p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 150 : 177-185, 1997.
PubMed
28. Vasen HF, et al : IGC-HNPCC : new clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International collaborative group on HNPCC. Gastroenterol 116 : 1453-1456, 1999.
 
29. Woodster R, et al : Identification of the breast cancer susceptibility gene BRCA2. Nature 378 : 789-792, 1995.
 
21 Meijers-Heijboer EJ, et al : Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 : 2015-2020, 2000.
 

症例から学ぶ 婦人科腫瘍学入門 文献

P.279 掲載の参考文献
1. 植木寛 : コルポスコピー入門と応用. 永井書店, 大阪, 1998.
 
2. 宮路徹ほか : 産婦人科病理学診断図譜. 杏林出版, 東京, 1988.
 
3. 日産婦医会編 : 子宮癌検診の手引き. 日産婦医会誌, 1997.
 
4. 日産婦学会・日病理学会編 : 絨毛性疾患取り扱い規約. 改訂第2版, 金原出版, 東京, 1997.
 
5. 日産婦学会・日病理学会・日放射線学会編 : 子宮体癌取り扱い規約. 改訂第2版, 金原出版, 東京, 1997.
 
6. 日産婦学会編 : 子宮内膜症取り扱い規約. 第一部, 金原出版, 東京, 1993.
 
7. 日産婦学会編 : 産科婦人科用語集・用語解説集. 金原出版, 東京, 2003.
 
8. 日産婦学会編 : 子宮内膜症取り扱い規約. 第二部, 金原出版, 東京, 2004.
 
9. 日産婦学会・日病理学会・日放射線学会編 : 子宮頸部癌取り扱い規約. 改訂第2版, 金原出版, 東京, 1997.
 
10. 日産婦学会・日本病理学会編 : 卵巣腫瘍取り扱い規約. 改訂第2版, 金原出版, 東京, 1990.
 
11. 日婦腫瘍学会 : 新コルポスコピースタンダードアトラス. 中外医学社, 東京, 2005.
 
12. Bereck JS & Hacker NF : Practical Gynecologic Oncology. 3rd ed, Lippincott Williams&Wilkins, New York, 2000.
 
13. Bereck JS : Novak's Gynecology. 13rd ed, Lippincott Williams&Wilkins, New York, 2002.
 
14. Clement PB & Young RH : Atlas of Gynecologic Surgical Pathology. WB Saunders, New York, 2000.
 
15. DiSaia PJ & Creasman WT : Clinical Gynecologic Oncology. WB Saunders, New York, 2000.
 
16. Griffiths CT, Silverstone A, Tabias J, Benjamin E : Gynecologic Oncology. Mosby-Wolfe Co, London, 1997.
 
17. Hendrickson MR & Kempson RL : Surgical Pathology of the Uterine Corpus, London, WB Saunders, 1980.
 
18. Kurman RJ : Blaustein's Pathology of the Female Genital Tract. 5th ed, Springer, New York, 2002.
 
19. Ozols RF : Ovarian Cancer. BC Decker Inc Hamilton, 2003.
 
20. Plenti AA & Friedman EA : Lymphatic System of the Female Genitalia. WB Saunders, New York, 1971.
 
21. Robboy SJ, Anderson MC, Russel P : Pathology of the Female Reproductive Tract. Churchill Livingstone, London, 2002.
 
22. Rubin SC & Sutton GP : Ovarian Cancer. 2nd ed, Lippincott Williams&Wilkins, Philadelphia, 2001.
 
23. Scully RE, Bonfiglio TA, Kurman RJ : Hitological typing of the genital tract tumours. 2nd ed, WHO Springer-Verlag, Berlin, 1994.
 
24. Scully RE, et al : Atlas of Tumor Pathology : Tumors of the Ovary, maldeveloped gonads, fallopian tube, and broad ligament. Armed Forces Inst Pathol, Washington DC, 1998.
 
25. Silverberg SG & Kuman RJ : Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. Armed Forces Inst Pathol, Washington DC, 1991.
 
26. Singer A & Monaghan JM : Lower Genital Tract Precancer. Colposcopy, Pathology, and Treatment. 2nd ed, Blackwell Science, London, 2000.
 
27. Stevens A & Lowe J : Human Histology. Times Mirror International Publishers Ltd, 1997.
 
28. TNM : Clsassification of Malignant Tumours. 6th ed, International Union against cancer UICC. Wiley-Liss, New York, 2002.
 
29. Tannock IF & Hill RP : The Basic Science of Oncology. 2nd ed, McGraw-Hill, Toronto, 1992.
 
30. Tavassoh FA & Devilee P (eds) : WHO Classification of Tumours. Pathology&Genetics, Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, 2003.
 
31. WHO handbook for reporting results of cancer treatment : WHO Offset Publication, No48, 1979.
 
32. Wilkinson EJ : Pathology of the Vulva and Vagina. Churchill Livingstone, New York. 1987.
 

書評

最近チェックした商品履歴

Loading...